[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f9BLT3WO6wTpoz_xSulU8_BP9SWjpgdsvdhVeOoepi1c":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":34,"phaseBuckets":85,"rows":92},"Charite University, Berlin, Germany",[4],841,false,112,57,3732062,18,658,[14,17,19,22,24,27,30,32],{"name":15,"count":16},"Stroke",24,{"name":18,"count":11},"Healthy",{"name":20,"count":21},"Delirium",12,{"name":23,"count":21},"Multiple Sclerosis",{"name":25,"count":26},"Heart Failure",11,{"name":28,"count":29},"Critical Illness",10,{"name":31,"count":29},"Depression",{"name":33,"count":29},"Ankylosing Spondylitis",[35,40,45,50,55,60,65,70,75,80],{"nctId":36,"briefTitle":37,"date":38,"intervention":39},"NCT04871269","The Effect of Dronabinol on the Acquisition and Consolidation of Trauma-Associated Memories","2023-12-31","Dronabinol",{"nctId":41,"briefTitle":42,"date":43,"intervention":44},"NCT05992272","Cue Effects in Human Addiction: Pavlovian to Instrumental Transfer","2024-12-31","fMRI imaging",{"nctId":46,"briefTitle":47,"date":48,"intervention":49},"NCT06225544","Lumasiran in Hyperoxalaemic Patients on Haemodialysis","2025-01-30","Lumasiran",{"nctId":51,"briefTitle":52,"date":53,"intervention":54},"NCT06112665","ToFAcitinib in Early Active Axial SpondyloarThritis:","2025-03","Tofacitinib 5 MG",{"nctId":56,"briefTitle":57,"date":58,"intervention":59},"NCT05697640","Study to Investigate Improvement in Physical Function in SF-36 With Vericiguat Compared With Placebo in Participants With Post-COVID-19 Syndrome","2026-04-01","Vericiguat Oral",{"nctId":61,"briefTitle":62,"date":63,"intervention":64},"NCT05909267","Dopamine Modulation of Motivation and Motor Function in Major Depression & Inflammation","2026-07","L-dopa\u002FCarbidopa",{"nctId":66,"briefTitle":67,"date":68,"intervention":69},"NCT04732910","Modulate-CF: Cystic Fibrosis Transmembrane Regulator (CFTR) Biomarker Study to Evaluate the Rescue of Mutant CFTR in Patients With Cystic Fibrosis Treated With CFTR-modulators","2027-03-31","Treatment with cystic fibrosis transmembrane regulator (CFTR) modualtors Ivacaftor, Lumacaftor-Ivacaftor, Tezacaftor-Ivacaftor, Elexacaftor-Tezacaftor-Ivacaftor, Vanzacaftor-Tezacaftor-Deutivacaftor",{"nctId":71,"briefTitle":72,"date":73,"intervention":74},"NCT06475495","Comparison of B-cell Depletion by Rituximab and Anti-CD 19 CAR-T Therapy in Patients With Rheumatoid Arthritis","2027-06","KYV101",{"nctId":76,"briefTitle":77,"date":78,"intervention":79},"NCT05665608","Prevention Of Sudden Cardiac Death After Myocardial Infarction by Defibrillator Implantation","2027-11-30","Optimal Medical Therapy",{"nctId":81,"briefTitle":82,"date":83,"intervention":84},"NCT03590171","International Study for Treatment of High Risk Childhood Relapsed ALL 2010","2027-12-31","Bortezomib",[86,87,88,89,90,91],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[93,118,145,170,188,248,280,307,325,343,364,386,413,431,452,478,499,528,549,598,632,667,709,740,758,783,808,834,852,877,903,921,947,965,991,1015,1041,1067,1085,1107,1133,1151,1176,1202,1227,1250,1268,1286,1304,1322,1340,1358,1376,1402,1426,1451,1477,1495,1519,1543,1572,1590,1608,1626,1644,1669,1687,1710,1753,1792,1814,1850,1884,1911,1935,1953,1971,1998,2016,2040,2058,2085,2103,2121,2145,2171,2197,2220,2244,2267,2291,2314,2337,2366,2384,2406,2430,2453,2477,2495,2513,2537,2555,2599,2630,2663,2694,2728,2757,2793,2816,2840,2862,2886,2904,2922,2947,2973,2997,3020,3044,3068,3091,3109,3127,3150,3174,3201,3219,3243,3264,3289,3307,3329,3354,3380,3398,3422,3446,3464,3487,3511,3529,3547,3571,3594,3617,3641,3668,3686,3704,3730,3748,3770,3793,3817,3840,3865,3883,3907,3925,3946,3970,3988,4011,4033,4051,4073,4096,4120,4146,4164,4189,4213,4241,4268,4292,4317,4335,4357,4378,4400,4442,4467,4499,4525,4559,4581,4605,4630,4654,4677,4698,4723,4741,4766,4792,4815,4840,4858,4880,4903,4928,4946,4970,4999,5017,5035,5053,5078,5102,5128,5153,5171,5197,5221,5239,5257,5282,5307,5333],{"intervention":54,"totalTrials":94,"cells":95},1,{"EARLY_PHASE1":96,"PHASE1":99,"PHASE2":101,"PHASE3":103,"PHASE4":105,"NA":116},{"trials":97,"activeCount":98},[],0,{"trials":100,"activeCount":98},[],{"trials":102,"activeCount":98},[],{"trials":104,"activeCount":98},[],{"trials":106,"activeCount":94,"soonestReadout":53},[107],{"nctId":51,"briefTitle":52,"status":108,"phases":109,"primaryCompletion":53,"completion":110,"start":111,"enrollment":112,"conditions":113,"interventions":115},"RECRUITING",[90],"2026-06","2023-11-10",104,[114],"Axial Spondyloarthritis",[54],{"trials":117,"activeCount":98},[],{"intervention":119,"totalTrials":94,"cells":120},"FOLFIRI+cetuximab",{"EARLY_PHASE1":121,"PHASE1":123,"PHASE2":125,"PHASE3":127,"PHASE4":141,"NA":143},{"trials":122,"activeCount":98},[],{"trials":124,"activeCount":98},[],{"trials":126,"activeCount":98},[],{"trials":128,"activeCount":94,"soonestReadout":134},[129],{"nctId":130,"briefTitle":131,"status":132,"phases":133,"primaryCompletion":134,"completion":135,"start":136,"enrollment":137,"conditions":138,"interventions":140},"NCT07004413","Continuous or Intermittent Cetuximab Plus FOLFIRI as First-line Treatment in RAS\u002FBRAF Wild-type mCRC Patients","NOT_YET_RECRUITING",[89],"2028-01-01","2031-01-01","2026-01-01",267,[139],"Colorectal Cancer Metastatic",[119],{"trials":142,"activeCount":98},[],{"trials":144,"activeCount":98},[],{"intervention":146,"totalTrials":94,"cells":147},"Inotuzumab ozogamicin",{"EARLY_PHASE1":148,"PHASE1":150,"PHASE2":152,"PHASE3":154,"PHASE4":166,"NA":168},{"trials":149,"activeCount":98},[],{"trials":151,"activeCount":98},[],{"trials":153,"activeCount":98},[],{"trials":155,"activeCount":94,"soonestReadout":160},[156],{"nctId":157,"briefTitle":158,"status":132,"phases":159,"primaryCompletion":160,"completion":160,"start":58,"enrollment":161,"conditions":162,"interventions":164},"NCT07476729","International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020)",[89],"2033-03-31",750,[163],"B-Cell Acute Lymphoblastic Leukaemia",[146,165],"Blinatumomab",{"trials":167,"activeCount":98},[],{"trials":169,"activeCount":98},[],{"intervention":165,"totalTrials":94,"cells":171},{"EARLY_PHASE1":172,"PHASE1":174,"PHASE2":176,"PHASE3":178,"PHASE4":184,"NA":186},{"trials":173,"activeCount":98},[],{"trials":175,"activeCount":98},[],{"trials":177,"activeCount":98},[],{"trials":179,"activeCount":94,"soonestReadout":160},[180],{"nctId":157,"briefTitle":158,"status":132,"phases":181,"primaryCompletion":160,"completion":160,"start":58,"enrollment":161,"conditions":182,"interventions":183},[89],[163],[146,165],{"trials":185,"activeCount":98},[],{"trials":187,"activeCount":98},[],{"intervention":189,"totalTrials":190,"cells":191},"Rituximab",4,{"EARLY_PHASE1":192,"PHASE1":194,"PHASE2":196,"PHASE3":232,"PHASE4":244,"NA":246},{"trials":193,"activeCount":98},[],{"trials":195,"activeCount":98},[],{"trials":197,"activeCount":94,"soonestReadout":73},[198,211,224],{"nctId":199,"briefTitle":200,"status":201,"phases":202,"primaryCompletion":203,"completion":204,"start":205,"enrollment":206,"conditions":207,"interventions":209},"NCT01458548","Sequential Treatment of CD20-positive Posttransplant Lymphoproliferative Disorder (PTLD)","TERMINATED",[88],"2008-05","2011-10","2002-12",70,[208],"Post-transplantation Lymphoproliferative Disorder",[189,210],"CHOP",{"nctId":212,"briefTitle":213,"status":214,"phases":215,"primaryCompletion":216,"completion":217,"start":218,"enrollment":219,"conditions":220,"interventions":222},"NCT00772655","Zevalin® First Line in Follicular Lymphoma","UNKNOWN",[88],"2010-06","2015-06","2007-10",60,[221],"Follicular Lymphoma",[223,189],"90Yttrium-Ibritumomab Tiuxetan (Zevalin®)+Rituximab",{"nctId":71,"briefTitle":72,"status":225,"phases":226,"primaryCompletion":73,"completion":73,"start":227,"enrollment":228,"conditions":229,"interventions":231},"ACTIVE_NOT_RECRUITING",[87,88],"2024-12-04",13,[230],"Rheumatoid Arthritis",[74,189],{"trials":233,"activeCount":98},[234],{"nctId":235,"briefTitle":236,"status":214,"phases":237,"completion":238,"start":239,"enrollment":240,"conditions":241,"interventions":242},"NCT00432653","Open Label Clinical Trial With Rituximab (MabThera ®) in Ankylosing Spondylitis",[88,89],"2009-11","2007-03",20,[33],[243],"rituximab",{"trials":245,"activeCount":98},[],{"trials":247,"activeCount":98},[],{"intervention":84,"totalTrials":249,"cells":250},2,{"EARLY_PHASE1":251,"PHASE1":253,"PHASE2":255,"PHASE3":274,"PHASE4":276,"NA":278},{"trials":252,"activeCount":98},[],{"trials":254,"activeCount":98},[],{"trials":256,"activeCount":94,"soonestReadout":83},[257,264],{"nctId":81,"briefTitle":82,"status":108,"phases":258,"primaryCompletion":83,"completion":83,"start":259,"enrollment":260,"conditions":261,"interventions":263},[88],"2017-09-01",250,[262],"Acute Lymphoblastic Leukemia (ALL)",[84],{"nctId":265,"briefTitle":266,"status":201,"phases":267,"primaryCompletion":268,"completion":268,"start":269,"enrollment":26,"conditions":270,"interventions":273},"NCT02102594","Therapy of Antibody-mediated Autoimmune Diseases by Bortezomib (TAVAB)",[88],"2019-08-30","2014-10",[271,272,230],"Myasthenia Gravis","Systemic Lupus Erythematosus",[84],{"trials":275,"activeCount":98},[],{"trials":277,"activeCount":98},[],{"trials":279,"activeCount":98},[],{"intervention":49,"totalTrials":94,"cells":281},{"EARLY_PHASE1":282,"PHASE1":284,"PHASE2":286,"PHASE3":301,"PHASE4":303,"NA":305},{"trials":283,"activeCount":98},[],{"trials":285,"activeCount":98},[],{"trials":287,"activeCount":94,"soonestReadout":48},[288],{"nctId":46,"briefTitle":47,"status":108,"phases":289,"primaryCompletion":48,"completion":290,"start":291,"enrollment":292,"conditions":293,"interventions":299},[88],"2025-03-01","2024-04-14",50,[294,295,296,297,298],"Haemodialysis","Chronic Kidney Disease Requiring Chronic Dialysis","Cardiovascular Disease","Cardiovascular Risk Factor","Hyperoxalemia",[49,300],"0.9% Sodium Chloride",{"trials":302,"activeCount":98},[],{"trials":304,"activeCount":98},[],{"trials":306,"activeCount":98},[],{"intervention":300,"totalTrials":94,"cells":308},{"EARLY_PHASE1":309,"PHASE1":311,"PHASE2":313,"PHASE3":319,"PHASE4":321,"NA":323},{"trials":310,"activeCount":98},[],{"trials":312,"activeCount":98},[],{"trials":314,"activeCount":94,"soonestReadout":48},[315],{"nctId":46,"briefTitle":47,"status":108,"phases":316,"primaryCompletion":48,"completion":290,"start":291,"enrollment":292,"conditions":317,"interventions":318},[88],[294,295,296,297,298],[49,300],{"trials":320,"activeCount":98},[],{"trials":322,"activeCount":98},[],{"trials":324,"activeCount":98},[],{"intervention":74,"totalTrials":94,"cells":326},{"EARLY_PHASE1":327,"PHASE1":329,"PHASE2":331,"PHASE3":337,"PHASE4":339,"NA":341},{"trials":328,"activeCount":98},[],{"trials":330,"activeCount":98},[],{"trials":332,"activeCount":94,"soonestReadout":73},[333],{"nctId":71,"briefTitle":72,"status":225,"phases":334,"primaryCompletion":73,"completion":73,"start":227,"enrollment":228,"conditions":335,"interventions":336},[87,88],[230],[74,189],{"trials":338,"activeCount":98},[],{"trials":340,"activeCount":98},[],{"trials":342,"activeCount":98},[],{"intervention":59,"totalTrials":94,"cells":344},{"EARLY_PHASE1":345,"PHASE1":347,"PHASE2":349,"PHASE3":358,"PHASE4":360,"NA":362},{"trials":346,"activeCount":98},[],{"trials":348,"activeCount":98},[],{"trials":350,"activeCount":94,"soonestReadout":58},[351],{"nctId":56,"briefTitle":57,"status":225,"phases":352,"primaryCompletion":58,"completion":353,"start":354,"enrollment":112,"conditions":355,"interventions":357},[88],"2026-12-31","2023-06-22",[356],"Post-COVID ME\u002FCFS",[59],{"trials":359,"activeCount":98},[],{"trials":361,"activeCount":98},[],{"trials":363,"activeCount":98},[],{"intervention":79,"totalTrials":94,"cells":365},{"EARLY_PHASE1":366,"PHASE1":368,"PHASE2":370,"PHASE3":372,"PHASE4":374,"NA":376},{"trials":367,"activeCount":98},[],{"trials":369,"activeCount":98},[],{"trials":371,"activeCount":98},[],{"trials":373,"activeCount":98},[],{"trials":375,"activeCount":98},[],{"trials":377,"activeCount":94,"soonestReadout":78},[378],{"nctId":76,"briefTitle":77,"status":108,"phases":379,"primaryCompletion":78,"completion":78,"start":380,"enrollment":381,"conditions":382,"interventions":385},[91],"2023-11-16",3595,[383,384],"Sudden Cardiac Death","Myocardial Infarction",[79],{"intervention":44,"totalTrials":94,"cells":387},{"EARLY_PHASE1":388,"PHASE1":390,"PHASE2":392,"PHASE3":394,"PHASE4":396,"NA":398},{"trials":389,"activeCount":98},[],{"trials":391,"activeCount":98},[],{"trials":393,"activeCount":98},[],{"trials":395,"activeCount":98},[],{"trials":397,"activeCount":98},[],{"trials":399,"activeCount":94,"soonestReadout":43},[400],{"nctId":41,"briefTitle":42,"status":108,"phases":401,"primaryCompletion":43,"completion":43,"start":402,"enrollment":403,"conditions":404,"interventions":411},[],"2020-11-24",300,[405,406,407,408,409,410],"Alcohol Use Disorder (AUD)","Alcoholism","Substance Use Disorders","Smoking, Tobacco","Stress Reaction","Stress",[44,412],"sMRI",{"intervention":412,"totalTrials":94,"cells":414},{"EARLY_PHASE1":415,"PHASE1":417,"PHASE2":419,"PHASE3":421,"PHASE4":423,"NA":425},{"trials":416,"activeCount":98},[],{"trials":418,"activeCount":98},[],{"trials":420,"activeCount":98},[],{"trials":422,"activeCount":98},[],{"trials":424,"activeCount":98},[],{"trials":426,"activeCount":94,"soonestReadout":43},[427],{"nctId":41,"briefTitle":42,"status":108,"phases":428,"primaryCompletion":43,"completion":43,"start":402,"enrollment":403,"conditions":429,"interventions":430},[],[405,406,407,408,409,410],[44,412],{"intervention":69,"totalTrials":94,"cells":432},{"EARLY_PHASE1":433,"PHASE1":435,"PHASE2":437,"PHASE3":439,"PHASE4":441,"NA":443},{"trials":434,"activeCount":98},[],{"trials":436,"activeCount":98},[],{"trials":438,"activeCount":98},[],{"trials":440,"activeCount":98},[],{"trials":442,"activeCount":98},[],{"trials":444,"activeCount":94,"soonestReadout":68},[445],{"nctId":66,"briefTitle":67,"status":108,"phases":446,"primaryCompletion":68,"completion":83,"start":447,"enrollment":448,"conditions":449,"interventions":451},[],"2018-07-01",500,[450],"Cystic Fibrosis",[69],{"intervention":453,"totalTrials":94,"cells":454},"off-label compassionate drug use",{"EARLY_PHASE1":455,"PHASE1":457,"PHASE2":459,"PHASE3":461,"PHASE4":463,"NA":465},{"trials":456,"activeCount":98},[],{"trials":458,"activeCount":98},[],{"trials":460,"activeCount":98},[],{"trials":462,"activeCount":98},[],{"trials":464,"activeCount":98},[],{"trials":466,"activeCount":94,"soonestReadout":471},[467],{"nctId":468,"briefTitle":469,"status":108,"phases":470,"primaryCompletion":471,"completion":471,"start":472,"enrollment":473,"conditions":474,"interventions":477},"NCT06967831","Drug Repurposing for Mitochondrial Disorders Using iPSCs Derived Neural Cells",[],"2030-02-28","2020-03-01",80,[475,476],"Leigh Syndrome (Maternally Inherited, MILS)","Leigh Syndrome (AR, AD, XR)",[453],{"intervention":64,"totalTrials":94,"cells":479},{"EARLY_PHASE1":480,"PHASE1":482,"PHASE2":484,"PHASE3":486,"PHASE4":488,"NA":490},{"trials":481,"activeCount":98},[],{"trials":483,"activeCount":98},[],{"trials":485,"activeCount":98},[],{"trials":487,"activeCount":98},[],{"trials":489,"activeCount":98},[],{"trials":491,"activeCount":94,"soonestReadout":63},[492],{"nctId":61,"briefTitle":62,"status":108,"phases":493,"primaryCompletion":63,"completion":63,"start":494,"enrollment":495,"conditions":496,"interventions":498},[91],"2023-07-26",165,[497],"Depressive Disorder, Major",[64],{"intervention":500,"totalTrials":94,"cells":501},"Estradiol Valerate",{"EARLY_PHASE1":502,"PHASE1":504,"PHASE2":506,"PHASE3":508,"PHASE4":510,"NA":512},{"trials":503,"activeCount":98},[],{"trials":505,"activeCount":98},[],{"trials":507,"activeCount":98},[],{"trials":509,"activeCount":98},[],{"trials":511,"activeCount":98},[],{"trials":513,"activeCount":94,"soonestReadout":83},[514],{"nctId":515,"briefTitle":516,"status":108,"phases":517,"primaryCompletion":83,"completion":518,"start":519,"enrollment":520,"conditions":521,"interventions":527},"NCT07419594","Estradiol and Intrusive Memories",[91],"2028-02-29","2024-08-19",273,[522,523,524,525,526],"PTSD","Intrusive Memories","Intrusion Symptom","Trauma","Intrusion",[500],{"intervention":39,"totalTrials":94,"cells":529},{"EARLY_PHASE1":530,"PHASE1":532,"PHASE2":534,"PHASE3":536,"PHASE4":538,"NA":540},{"trials":531,"activeCount":98},[],{"trials":533,"activeCount":98},[],{"trials":535,"activeCount":98},[],{"trials":537,"activeCount":98},[],{"trials":539,"activeCount":98},[],{"trials":541,"activeCount":94,"soonestReadout":38},[542],{"nctId":36,"briefTitle":37,"status":225,"phases":543,"primaryCompletion":38,"completion":544,"start":545,"enrollment":546,"conditions":547,"interventions":548},[91],"2025-08-28","2021-05-01",291,[523],[39],{"intervention":550,"totalTrials":551,"cells":552},"Olanzapine",3,{"EARLY_PHASE1":553,"PHASE1":555,"PHASE2":557,"PHASE3":559,"PHASE4":583,"NA":596},{"trials":554,"activeCount":98},[],{"trials":556,"activeCount":98},[],{"trials":558,"activeCount":98},[],{"trials":560,"activeCount":98},[561,572],{"nctId":562,"briefTitle":563,"status":564,"phases":565,"primaryCompletion":566,"completion":566,"start":567,"enrollment":568,"conditions":569,"interventions":571},"NCT00876772","Olanzapine for the Treatment of Appetite Loss in Amyotrophic Lateral Sclerosis (ALS)","COMPLETED",[88,89],"2012-07","2011-03",40,[570],"Amyotrophic Lateral Sclerosis (ALS)",[550],{"nctId":573,"briefTitle":574,"status":575,"phases":576,"primaryCompletion":577,"completion":578,"start":218,"enrollment":98,"conditions":579,"interventions":582},"NCT00568672","Optimal Duration of Olanzapine Add-on Therapy in Major Depression","WITHDRAWN",[89],"2008-01","2008-04",[580,581],"Relapse Rate of a Major Depressive Episode","Safety of Olanzapine in Subjects With Major Depression",[550],{"trials":584,"activeCount":98},[585],{"nctId":586,"briefTitle":587,"status":564,"phases":588,"primaryCompletion":239,"completion":589,"start":590,"enrollment":568,"conditions":591,"interventions":593},"NCT00148564","Energy Homeostasis Under Treatment With Atypical Antipsychotics",[90],"2007-06","2004-03",[592],"Schizophrenia",[594,595],"olanzapine","Ziprasidone",{"trials":597,"activeCount":98},[],{"intervention":599,"totalTrials":249,"cells":600},"Methotrexate",{"EARLY_PHASE1":601,"PHASE1":603,"PHASE2":605,"PHASE3":615,"PHASE4":617,"NA":630},{"trials":602,"activeCount":98},[],{"trials":604,"activeCount":98},[],{"trials":606,"activeCount":98},[607],{"nctId":608,"briefTitle":609,"status":214,"phases":610,"completion":611,"start":612,"enrollment":240,"conditions":613,"interventions":614},"NCT00243750","Methotrexate in Ankylosing Spondylitis (MTX in AS)",[88],"2005-11","2003-09",[33],[599],{"trials":616,"activeCount":98},[],{"trials":618,"activeCount":98},[619],{"nctId":620,"briefTitle":621,"status":564,"phases":622,"completion":623,"start":624,"enrollment":625,"conditions":626,"interventions":628},"NCT00153530","Whole Brain Irradiation in Primary Central Nervous System (CNS) Lymphoma (PCNSL)",[90],"2009-05","2000-05",604,[627],"Central Nervous System Lymphoma",[629],"methotrexate",{"trials":631,"activeCount":98},[],{"intervention":633,"totalTrials":249,"cells":634},"desloratadine",{"EARLY_PHASE1":635,"PHASE1":637,"PHASE2":639,"PHASE3":641,"PHASE4":653,"NA":665},{"trials":636,"activeCount":98},[],{"trials":638,"activeCount":98},[],{"trials":640,"activeCount":98},[],{"trials":642,"activeCount":98},[643],{"nctId":644,"briefTitle":645,"status":564,"phases":646,"primaryCompletion":647,"completion":647,"start":648,"enrollment":649,"conditions":650,"interventions":652},"NCT00598611","Effects of 5 mg vs. 20 mg Desloratadine on Skin Lesions in Patients With Chronic Urticaria (CU)",[89],"2009-08","2007-09",29,[651],"Chronic Urticaria",[633,633],{"trials":654,"activeCount":98},[655],{"nctId":656,"briefTitle":657,"status":564,"phases":658,"primaryCompletion":659,"start":660,"enrollment":661,"conditions":662,"interventions":664},"NCT00600847","A Study to Assess and Compare the Effects of 5 mg vs. 20 mg Desloratadine on the Development of Cold Urticaria Lesions",[90],"2007-11","2006-11",33,[663],"Acquired Cold Urticaria",[633,633],{"trials":666,"activeCount":98},[],{"intervention":668,"totalTrials":249,"cells":669},"Rivaroxaban",{"EARLY_PHASE1":670,"PHASE1":672,"PHASE2":674,"PHASE3":686,"PHASE4":688,"NA":707},{"trials":671,"activeCount":98},[],{"trials":673,"activeCount":98},[],{"trials":675,"activeCount":98},[676],{"nctId":677,"briefTitle":678,"status":201,"phases":679,"primaryCompletion":680,"completion":680,"start":681,"enrollment":682,"conditions":683,"interventions":685},"NCT04416048","Effect of Anticoagulation Therapy on Clinical Outcomes in COVID-19",[88],"2021-07-20","2020-11-30",111,[684],"COVID-19",[668],{"trials":687,"activeCount":98},[],{"trials":689,"activeCount":98},[690],{"nctId":691,"briefTitle":692,"status":564,"phases":693,"primaryCompletion":694,"completion":694,"start":695,"enrollment":696,"conditions":697,"interventions":699},"NCT03463317","Left Atrial Appendage CLOSURE in Patients With Atrial Fibrillation Compared to Medical Therapy",[90],"2024-11-30","2018-02-28",912,[698],"Atrial Fibrillation",[700,701,702,668,703,704,705,706],"Acetylsalicylic acid","Clopidogrel","Dabigatran","Apixaban","Edoxaban","Phenprocoumon","Warfarin",{"trials":708,"activeCount":98},[],{"intervention":710,"totalTrials":94,"cells":711},"Bisoprolol",{"EARLY_PHASE1":712,"PHASE1":714,"PHASE2":716,"PHASE3":718,"PHASE4":720,"NA":738},{"trials":713,"activeCount":98},[],{"trials":715,"activeCount":98},[],{"trials":717,"activeCount":98},[],{"trials":719,"activeCount":98},[],{"trials":721,"activeCount":98},[722],{"nctId":723,"briefTitle":724,"status":214,"phases":725,"primaryCompletion":726,"completion":726,"start":727,"enrollment":728,"conditions":729,"interventions":736},"NCT05294887","Randomized Trial to Examine a Differential Therapeutic Response in Symptomatic Patients With Non-obstructive Coronary Artery Disease",[90],"2024-06","2022-03-04",132,[730,731,732,733,734,735],"Coronary Microvascular Dysfunction","Microvascular Angina","Vasospasm, Coronary","Vasospastic Angina","Prinzmetal Angina","Coronary Artery Disease",[710,737],"Diltiazem",{"trials":739,"activeCount":98},[],{"intervention":737,"totalTrials":94,"cells":741},{"EARLY_PHASE1":742,"PHASE1":744,"PHASE2":746,"PHASE3":748,"PHASE4":750,"NA":756},{"trials":743,"activeCount":98},[],{"trials":745,"activeCount":98},[],{"trials":747,"activeCount":98},[],{"trials":749,"activeCount":98},[],{"trials":751,"activeCount":98},[752],{"nctId":723,"briefTitle":724,"status":214,"phases":753,"primaryCompletion":726,"completion":726,"start":727,"enrollment":728,"conditions":754,"interventions":755},[90],[730,731,732,733,734,735],[710,737],{"trials":757,"activeCount":98},[],{"intervention":759,"totalTrials":94,"cells":760},"Amlodipine",{"EARLY_PHASE1":761,"PHASE1":763,"PHASE2":765,"PHASE3":767,"PHASE4":769,"NA":781},{"trials":762,"activeCount":98},[],{"trials":764,"activeCount":98},[],{"trials":766,"activeCount":98},[],{"trials":768,"activeCount":98},[],{"trials":770,"activeCount":98},[771],{"nctId":772,"briefTitle":773,"status":564,"phases":774,"completion":775,"start":776,"enrollment":777,"conditions":778,"interventions":780},"NCT00124969","Influence of Amlodipine on the Mortality of Patients With End-Stage Renal Failure",[90],"2006-10","2002-01",356,[779],"Kidney Failure, Chronic",[759],{"trials":782,"activeCount":98},[],{"intervention":784,"totalTrials":94,"cells":785},"Infusion Therapy",{"EARLY_PHASE1":786,"PHASE1":788,"PHASE2":790,"PHASE3":792,"PHASE4":794,"NA":806},{"trials":787,"activeCount":98},[],{"trials":789,"activeCount":98},[],{"trials":791,"activeCount":98},[],{"trials":793,"activeCount":98},[],{"trials":795,"activeCount":98},[796],{"nctId":797,"briefTitle":798,"status":564,"phases":799,"primaryCompletion":800,"completion":801,"start":802,"enrollment":568,"conditions":803,"interventions":805},"NCT01117519","Impact of Fluid Management Within a Goal-directed Hemodynamic Protocol on Acid-base Balance in Elective Trauma Surgery",[90],"2011-06","2011-11","2010-05",[804],"Hemodynamic Instability",[784],{"trials":807,"activeCount":98},[],{"intervention":809,"totalTrials":94,"cells":810},"Ferric Carboxymaltose 50Mg\u002FMl Inj 15Ml",{"EARLY_PHASE1":811,"PHASE1":813,"PHASE2":815,"PHASE3":817,"PHASE4":819,"NA":832},{"trials":812,"activeCount":98},[],{"trials":814,"activeCount":98},[],{"trials":816,"activeCount":98},[],{"trials":818,"activeCount":98},[],{"trials":820,"activeCount":98},[821],{"nctId":822,"briefTitle":823,"status":564,"phases":824,"primaryCompletion":825,"completion":826,"start":827,"enrollment":568,"conditions":828,"interventions":830},"NCT03074591","Effect of IV Iron in Patients With Heart Failure With Preserved Ejection Fraction",[90],"2022-12-13","2024-04-10","2017-08-01",[829,25],"Iron-deficiency",[809,831],"Saline Solution for",{"trials":833,"activeCount":98},[],{"intervention":831,"totalTrials":94,"cells":835},{"EARLY_PHASE1":836,"PHASE1":838,"PHASE2":840,"PHASE3":842,"PHASE4":844,"NA":850},{"trials":837,"activeCount":98},[],{"trials":839,"activeCount":98},[],{"trials":841,"activeCount":98},[],{"trials":843,"activeCount":98},[],{"trials":845,"activeCount":98},[846],{"nctId":822,"briefTitle":823,"status":564,"phases":847,"primaryCompletion":825,"completion":826,"start":827,"enrollment":568,"conditions":848,"interventions":849},[90],[829,25],[809,831],{"trials":851,"activeCount":98},[],{"intervention":853,"totalTrials":94,"cells":854},"erythropoetin beta",{"EARLY_PHASE1":855,"PHASE1":857,"PHASE2":859,"PHASE3":861,"PHASE4":863,"NA":875},{"trials":856,"activeCount":98},[],{"trials":858,"activeCount":98},[],{"trials":860,"activeCount":98},[],{"trials":862,"activeCount":98},[],{"trials":864,"activeCount":98},[865],{"nctId":866,"briefTitle":867,"status":564,"phases":868,"primaryCompletion":869,"completion":869,"start":870,"enrollment":871,"conditions":872,"interventions":874},"NCT00568542","Chronic, Low Dose Erythropoetin Beta in Ischemic Cardiomyopathy",[90],"2008-10","2006-05",28,[873],"Ischemic Cardiomyopathy",[853],{"trials":876,"activeCount":98},[],{"intervention":878,"totalTrials":94,"cells":879},"Galantamine CR",{"EARLY_PHASE1":880,"PHASE1":882,"PHASE2":884,"PHASE3":886,"PHASE4":888,"NA":901},{"trials":881,"activeCount":98},[],{"trials":883,"activeCount":98},[],{"trials":885,"activeCount":98},[],{"trials":887,"activeCount":98},[],{"trials":889,"activeCount":98},[890],{"nctId":891,"briefTitle":892,"status":564,"phases":893,"primaryCompletion":894,"completion":623,"start":895,"enrollment":896,"conditions":897,"interventions":899},"NCT01921972","The Efficacy of a Combination Regimen in Patients With Mild to Moderate Probable Alzheimer's Disease",[90],"2008-11","2004-11",232,[898],"Alzheimer's Disease",[878,900],"Memantine",{"trials":902,"activeCount":98},[],{"intervention":900,"totalTrials":94,"cells":904},{"EARLY_PHASE1":905,"PHASE1":907,"PHASE2":909,"PHASE3":911,"PHASE4":913,"NA":919},{"trials":906,"activeCount":98},[],{"trials":908,"activeCount":98},[],{"trials":910,"activeCount":98},[],{"trials":912,"activeCount":98},[],{"trials":914,"activeCount":98},[915],{"nctId":891,"briefTitle":892,"status":564,"phases":916,"primaryCompletion":894,"completion":623,"start":895,"enrollment":896,"conditions":917,"interventions":918},[90],[898],[878,900],{"trials":920,"activeCount":98},[],{"intervention":922,"totalTrials":94,"cells":923},"Triamcinolone Acetonide",{"EARLY_PHASE1":924,"PHASE1":926,"PHASE2":928,"PHASE3":930,"PHASE4":932,"NA":945},{"trials":925,"activeCount":98},[],{"trials":927,"activeCount":98},[],{"trials":929,"activeCount":98},[],{"trials":931,"activeCount":98},[],{"trials":933,"activeCount":98},[934],{"nctId":935,"briefTitle":936,"status":214,"phases":937,"primaryCompletion":938,"completion":939,"start":940,"enrollment":292,"conditions":941,"interventions":944},"NCT02379000","TTT Versus TTT and Triamcinolone to Decrease Exudation in Choroidal Melanoma After Proton Beam Therapy",[90],"2017-12","2018-07","2015-01",[942,943],"Exudative Retinal Detachment","Uveal Melanoma",[922],{"trials":946,"activeCount":98},[],{"intervention":595,"totalTrials":94,"cells":948},{"EARLY_PHASE1":949,"PHASE1":951,"PHASE2":953,"PHASE3":955,"PHASE4":957,"NA":963},{"trials":950,"activeCount":98},[],{"trials":952,"activeCount":98},[],{"trials":954,"activeCount":98},[],{"trials":956,"activeCount":98},[],{"trials":958,"activeCount":98},[959],{"nctId":586,"briefTitle":587,"status":564,"phases":960,"primaryCompletion":239,"completion":589,"start":590,"enrollment":568,"conditions":961,"interventions":962},[90],[592],[594,595],{"trials":964,"activeCount":98},[],{"intervention":966,"totalTrials":94,"cells":967},"oral nutritional supplement rich in eicosapentanoic acid",{"EARLY_PHASE1":968,"PHASE1":970,"PHASE2":972,"PHASE3":974,"PHASE4":976,"NA":989},{"trials":969,"activeCount":98},[],{"trials":971,"activeCount":98},[],{"trials":973,"activeCount":98},[],{"trials":975,"activeCount":98},[],{"trials":977,"activeCount":98},[978],{"nctId":979,"briefTitle":980,"status":564,"phases":981,"primaryCompletion":660,"completion":589,"start":982,"enrollment":983,"conditions":984,"interventions":988},"NCT00168987","Influence of an Oral Nutritional Supplement Rich in Omega-3 Fatty Acids on Functional State and Quality of Life in Malnourished Patients With Gastroenterological Tumors",[90],"2005-01",30,[985,986,987],"Colorectal Neoplasms","Hepatocellular Carcinoma","Cholangiocarcinoma",[966],{"trials":990,"activeCount":98},[],{"intervention":992,"totalTrials":94,"cells":993},"Fresubin protein energy Drink",{"EARLY_PHASE1":994,"PHASE1":996,"PHASE2":998,"PHASE3":1000,"PHASE4":1002,"NA":1013},{"trials":995,"activeCount":98},[],{"trials":997,"activeCount":98},[],{"trials":999,"activeCount":98},[],{"trials":1001,"activeCount":98},[],{"trials":1003,"activeCount":98},[1004],{"nctId":1005,"briefTitle":1006,"status":564,"phases":1007,"primaryCompletion":1008,"completion":1009,"start":590,"conditions":1010,"interventions":1012},"NCT00168935","Malnutrition in Gastroenterology Patients",[90],"2007-08","2008-12",[1011],"Malnutrition",[992],{"trials":1014,"activeCount":98},[],{"intervention":1016,"totalTrials":94,"cells":1017},"Sulfadoxin",{"EARLY_PHASE1":1018,"PHASE1":1020,"PHASE2":1022,"PHASE3":1024,"PHASE4":1026,"NA":1039},{"trials":1019,"activeCount":98},[],{"trials":1021,"activeCount":98},[],{"trials":1023,"activeCount":98},[],{"trials":1025,"activeCount":98},[],{"trials":1027,"activeCount":98},[1028],{"nctId":1029,"briefTitle":1030,"status":214,"phases":1031,"completion":1032,"start":1033,"enrollment":1034,"conditions":1035,"interventions":1038},"NCT00168948","Intermittent Antimalaria Treatment With SP in African Children",[90],"2005-08","2003-03",1200,[1036,1037],"Malaria","Anemia",[1016],{"trials":1040,"activeCount":98},[],{"intervention":1042,"totalTrials":94,"cells":1043},"enteric-coated mycophenolate sodium",{"EARLY_PHASE1":1044,"PHASE1":1046,"PHASE2":1048,"PHASE3":1050,"PHASE4":1052,"NA":1065},{"trials":1045,"activeCount":98},[],{"trials":1047,"activeCount":98},[],{"trials":1049,"activeCount":98},[],{"trials":1051,"activeCount":98},[],{"trials":1053,"activeCount":98},[1054],{"nctId":1055,"briefTitle":1056,"status":564,"phases":1057,"completion":1058,"start":1059,"enrollment":1060,"conditions":1061,"interventions":1063},"NCT00443937","Pharmacokinetics of Everolimus and Enteric-Coated Mycophenolatesodium Before and After Withdrawal of Cyclosporine in Renal Transplant Patients",[90],"2006-03","2004-01",15,[1062],"Renal Transplantation",[1042,1064],"everolimus",{"trials":1066,"activeCount":98},[],{"intervention":1064,"totalTrials":94,"cells":1068},{"EARLY_PHASE1":1069,"PHASE1":1071,"PHASE2":1073,"PHASE3":1075,"PHASE4":1077,"NA":1083},{"trials":1070,"activeCount":98},[],{"trials":1072,"activeCount":98},[],{"trials":1074,"activeCount":98},[],{"trials":1076,"activeCount":98},[],{"trials":1078,"activeCount":98},[1079],{"nctId":1055,"briefTitle":1056,"status":564,"phases":1080,"completion":1058,"start":1059,"enrollment":1060,"conditions":1081,"interventions":1082},[90],[1062],[1042,1064],{"trials":1084,"activeCount":98},[],{"intervention":1086,"totalTrials":94,"cells":1087},"ibandronate, calcium and vitamin D",{"EARLY_PHASE1":1088,"PHASE1":1090,"PHASE2":1092,"PHASE3":1094,"PHASE4":1096,"NA":1105},{"trials":1089,"activeCount":98},[],{"trials":1091,"activeCount":98},[],{"trials":1093,"activeCount":98},[],{"trials":1095,"activeCount":98},[],{"trials":1097,"activeCount":98},[1098],{"nctId":1099,"briefTitle":1100,"status":564,"phases":1101,"primaryCompletion":648,"completion":648,"start":1058,"enrollment":206,"conditions":1102,"interventions":1104},"NCT00271713","Impact of Oral Ibandronate 150 mg Monthly on Structural Properties of Bone in Postmenopausal Osteoporosis (SPIMOS-3D)",[90],[1103],"Osteoporosis, Postmenopausal",[1086],{"trials":1106,"activeCount":98},[],{"intervention":1108,"totalTrials":94,"cells":1109},"Simvastatin 60 mg",{"EARLY_PHASE1":1110,"PHASE1":1112,"PHASE2":1114,"PHASE3":1116,"PHASE4":1118,"NA":1131},{"trials":1111,"activeCount":98},[],{"trials":1113,"activeCount":98},[],{"trials":1115,"activeCount":98},[],{"trials":1117,"activeCount":98},[],{"trials":1119,"activeCount":98},[1120],{"nctId":1121,"briefTitle":1122,"status":214,"phases":1123,"primaryCompletion":1124,"completion":1125,"start":1009,"enrollment":1126,"conditions":1127,"interventions":1129},"NCT00842920","Trial of Simvastatin in Amnestic Mild Cognitive Impairment (MCI) Patients",[90],"2020-08-31","2021-02-28",520,[1128],"Mild Cognitive Impairment",[1108,1130],"Simvastatin 20 mg",{"trials":1132,"activeCount":98},[],{"intervention":1130,"totalTrials":94,"cells":1134},{"EARLY_PHASE1":1135,"PHASE1":1137,"PHASE2":1139,"PHASE3":1141,"PHASE4":1143,"NA":1149},{"trials":1136,"activeCount":98},[],{"trials":1138,"activeCount":98},[],{"trials":1140,"activeCount":98},[],{"trials":1142,"activeCount":98},[],{"trials":1144,"activeCount":98},[1145],{"nctId":1121,"briefTitle":1122,"status":214,"phases":1146,"primaryCompletion":1124,"completion":1125,"start":1009,"enrollment":1126,"conditions":1147,"interventions":1148},[90],[1128],[1108,1130],{"trials":1150,"activeCount":98},[],{"intervention":1152,"totalTrials":94,"cells":1153},"Euminz®",{"EARLY_PHASE1":1154,"PHASE1":1156,"PHASE2":1158,"PHASE3":1160,"PHASE4":1162,"NA":1174},{"trials":1155,"activeCount":98},[],{"trials":1157,"activeCount":98},[],{"trials":1159,"activeCount":98},[],{"trials":1161,"activeCount":98},[],{"trials":1163,"activeCount":98},[1164],{"nctId":1165,"briefTitle":1166,"status":564,"phases":1167,"primaryCompletion":1168,"completion":1168,"start":1169,"enrollment":1170,"conditions":1171,"interventions":1173},"NCT01770080","Efficacy of Euminz® for Tension-Type Headache",[90],"2015-09","2013-02",211,[1172],"Episodic Tension-Type Headache",[1152],{"trials":1175,"activeCount":98},[],{"intervention":1177,"totalTrials":94,"cells":1178},"Fosfomycin",{"EARLY_PHASE1":1179,"PHASE1":1181,"PHASE2":1183,"PHASE3":1185,"PHASE4":1187,"NA":1200},{"trials":1180,"activeCount":98},[],{"trials":1182,"activeCount":98},[],{"trials":1184,"activeCount":98},[],{"trials":1186,"activeCount":98},[],{"trials":1188,"activeCount":98},[1189],{"nctId":1190,"briefTitle":1191,"status":214,"phases":1192,"primaryCompletion":1193,"completion":1194,"start":1195,"enrollment":1196,"conditions":1197,"interventions":1199},"NCT05211011","Efficacy and Safety of Intravenous Fosfomycin in Prosthetic Joint Infection",[90],"2022-04-30","2023-04-30","2018-01-23",226,[1198],"Prosthetic Joint Infection",[1177],{"trials":1201,"activeCount":98},[],{"intervention":1203,"totalTrials":94,"cells":1204},"Valsartan",{"EARLY_PHASE1":1205,"PHASE1":1207,"PHASE2":1209,"PHASE3":1211,"PHASE4":1213,"NA":1225},{"trials":1206,"activeCount":98},[],{"trials":1208,"activeCount":98},[],{"trials":1210,"activeCount":98},[],{"trials":1212,"activeCount":98},[],{"trials":1214,"activeCount":98},[1215],{"nctId":1216,"briefTitle":1217,"status":564,"phases":1218,"primaryCompletion":775,"completion":239,"start":1219,"enrollment":1220,"conditions":1221,"interventions":1224},"NCT00982358","Anti-Inflammatory Actions of Valsartan in Patients With Type 2 Diabetes Mellitus",[90],"2004-07",121,[1222,1223,735],"Hypertension","Type 2 Diabetes Mellitus",[1203],{"trials":1226,"activeCount":98},[],{"intervention":1228,"totalTrials":94,"cells":1229},"Irbesartan",{"EARLY_PHASE1":1230,"PHASE1":1232,"PHASE2":1234,"PHASE3":1236,"PHASE4":1238,"NA":1248},{"trials":1231,"activeCount":98},[],{"trials":1233,"activeCount":98},[],{"trials":1235,"activeCount":98},[],{"trials":1237,"activeCount":98},[],{"trials":1239,"activeCount":98},[1240],{"nctId":1241,"briefTitle":1242,"status":564,"phases":1243,"completion":589,"start":1219,"enrollment":1244,"conditions":1245,"interventions":1247},"NCT00347087","Effect of Irbesartan on Insulin Sensitivity in Chronic Heart Failure",[90],36,[1246],"Chronic Heart Failure",[1228],{"trials":1249,"activeCount":98},[],{"intervention":700,"totalTrials":94,"cells":1251},{"EARLY_PHASE1":1252,"PHASE1":1254,"PHASE2":1256,"PHASE3":1258,"PHASE4":1260,"NA":1266},{"trials":1253,"activeCount":98},[],{"trials":1255,"activeCount":98},[],{"trials":1257,"activeCount":98},[],{"trials":1259,"activeCount":98},[],{"trials":1261,"activeCount":98},[1262],{"nctId":691,"briefTitle":692,"status":564,"phases":1263,"primaryCompletion":694,"completion":694,"start":695,"enrollment":696,"conditions":1264,"interventions":1265},[90],[698],[700,701,702,668,703,704,705,706],{"trials":1267,"activeCount":98},[],{"intervention":701,"totalTrials":94,"cells":1269},{"EARLY_PHASE1":1270,"PHASE1":1272,"PHASE2":1274,"PHASE3":1276,"PHASE4":1278,"NA":1284},{"trials":1271,"activeCount":98},[],{"trials":1273,"activeCount":98},[],{"trials":1275,"activeCount":98},[],{"trials":1277,"activeCount":98},[],{"trials":1279,"activeCount":98},[1280],{"nctId":691,"briefTitle":692,"status":564,"phases":1281,"primaryCompletion":694,"completion":694,"start":695,"enrollment":696,"conditions":1282,"interventions":1283},[90],[698],[700,701,702,668,703,704,705,706],{"trials":1285,"activeCount":98},[],{"intervention":702,"totalTrials":94,"cells":1287},{"EARLY_PHASE1":1288,"PHASE1":1290,"PHASE2":1292,"PHASE3":1294,"PHASE4":1296,"NA":1302},{"trials":1289,"activeCount":98},[],{"trials":1291,"activeCount":98},[],{"trials":1293,"activeCount":98},[],{"trials":1295,"activeCount":98},[],{"trials":1297,"activeCount":98},[1298],{"nctId":691,"briefTitle":692,"status":564,"phases":1299,"primaryCompletion":694,"completion":694,"start":695,"enrollment":696,"conditions":1300,"interventions":1301},[90],[698],[700,701,702,668,703,704,705,706],{"trials":1303,"activeCount":98},[],{"intervention":703,"totalTrials":94,"cells":1305},{"EARLY_PHASE1":1306,"PHASE1":1308,"PHASE2":1310,"PHASE3":1312,"PHASE4":1314,"NA":1320},{"trials":1307,"activeCount":98},[],{"trials":1309,"activeCount":98},[],{"trials":1311,"activeCount":98},[],{"trials":1313,"activeCount":98},[],{"trials":1315,"activeCount":98},[1316],{"nctId":691,"briefTitle":692,"status":564,"phases":1317,"primaryCompletion":694,"completion":694,"start":695,"enrollment":696,"conditions":1318,"interventions":1319},[90],[698],[700,701,702,668,703,704,705,706],{"trials":1321,"activeCount":98},[],{"intervention":704,"totalTrials":94,"cells":1323},{"EARLY_PHASE1":1324,"PHASE1":1326,"PHASE2":1328,"PHASE3":1330,"PHASE4":1332,"NA":1338},{"trials":1325,"activeCount":98},[],{"trials":1327,"activeCount":98},[],{"trials":1329,"activeCount":98},[],{"trials":1331,"activeCount":98},[],{"trials":1333,"activeCount":98},[1334],{"nctId":691,"briefTitle":692,"status":564,"phases":1335,"primaryCompletion":694,"completion":694,"start":695,"enrollment":696,"conditions":1336,"interventions":1337},[90],[698],[700,701,702,668,703,704,705,706],{"trials":1339,"activeCount":98},[],{"intervention":705,"totalTrials":94,"cells":1341},{"EARLY_PHASE1":1342,"PHASE1":1344,"PHASE2":1346,"PHASE3":1348,"PHASE4":1350,"NA":1356},{"trials":1343,"activeCount":98},[],{"trials":1345,"activeCount":98},[],{"trials":1347,"activeCount":98},[],{"trials":1349,"activeCount":98},[],{"trials":1351,"activeCount":98},[1352],{"nctId":691,"briefTitle":692,"status":564,"phases":1353,"primaryCompletion":694,"completion":694,"start":695,"enrollment":696,"conditions":1354,"interventions":1355},[90],[698],[700,701,702,668,703,704,705,706],{"trials":1357,"activeCount":98},[],{"intervention":706,"totalTrials":94,"cells":1359},{"EARLY_PHASE1":1360,"PHASE1":1362,"PHASE2":1364,"PHASE3":1366,"PHASE4":1368,"NA":1374},{"trials":1361,"activeCount":98},[],{"trials":1363,"activeCount":98},[],{"trials":1365,"activeCount":98},[],{"trials":1367,"activeCount":98},[],{"trials":1369,"activeCount":98},[1370],{"nctId":691,"briefTitle":692,"status":564,"phases":1371,"primaryCompletion":694,"completion":694,"start":695,"enrollment":696,"conditions":1372,"interventions":1373},[90],[698],[700,701,702,668,703,704,705,706],{"trials":1375,"activeCount":98},[],{"intervention":1377,"totalTrials":94,"cells":1378},"alfacalcidol",{"EARLY_PHASE1":1379,"PHASE1":1381,"PHASE2":1383,"PHASE3":1385,"PHASE4":1387,"NA":1400},{"trials":1380,"activeCount":98},[],{"trials":1382,"activeCount":98},[],{"trials":1384,"activeCount":98},[],{"trials":1386,"activeCount":98},[],{"trials":1388,"activeCount":98},[1389],{"nctId":1390,"briefTitle":1391,"status":564,"phases":1392,"primaryCompletion":1393,"completion":203,"start":1394,"enrollment":1395,"conditions":1396,"interventions":1399},"NCT00168909","Influence of Alfacalcidol on Falls in Osteopenic\u002FOsteoporotic Postmenopausal Women (ALFA Study)",[90],"2007-07","2003-06",282,[1103,1397,1398],"Osteopenia","Falls",[1377],{"trials":1401,"activeCount":98},[],{"intervention":1403,"totalTrials":94,"cells":1404},"amodiaquine-artesunate versus amodiaquine",{"EARLY_PHASE1":1405,"PHASE1":1407,"PHASE2":1409,"PHASE3":1411,"PHASE4":1413,"NA":1424},{"trials":1406,"activeCount":98},[],{"trials":1408,"activeCount":98},[],{"trials":1410,"activeCount":98},[],{"trials":1412,"activeCount":98},[],{"trials":1414,"activeCount":98},[1415],{"nctId":1416,"briefTitle":1417,"status":214,"phases":1418,"completion":1419,"start":1420,"enrollment":1421,"conditions":1422,"interventions":1423},"NCT00238017","Efficacy and Safety of Amodiaquine and Amodiaquine-Artesunate",[90],"2005-12","2005-10",400,[1036],[1403],{"trials":1425,"activeCount":98},[],{"intervention":1427,"totalTrials":94,"cells":1428},"alendronate once weekly 70mg",{"EARLY_PHASE1":1429,"PHASE1":1431,"PHASE2":1433,"PHASE3":1435,"PHASE4":1437,"NA":1449},{"trials":1430,"activeCount":98},[],{"trials":1432,"activeCount":98},[],{"trials":1434,"activeCount":98},[],{"trials":1436,"activeCount":98},[],{"trials":1438,"activeCount":98},[1439],{"nctId":1440,"briefTitle":1441,"status":214,"phases":1442,"primaryCompletion":1443,"completion":1444,"start":1059,"enrollment":1445,"conditions":1446,"interventions":1448},"NCT00727493","Osteoporosis and Dental Implant",[90],"2010-01","2010-04",45,[1447],"Osteoporosis",[1427],{"trials":1450,"activeCount":98},[],{"intervention":1452,"totalTrials":94,"cells":1453},"Levocetirizine Oral",{"EARLY_PHASE1":1454,"PHASE1":1456,"PHASE2":1458,"PHASE3":1460,"PHASE4":1462,"NA":1475},{"trials":1455,"activeCount":98},[],{"trials":1457,"activeCount":98},[],{"trials":1459,"activeCount":98},[],{"trials":1461,"activeCount":98},[],{"trials":1463,"activeCount":98},[1464],{"nctId":1465,"briefTitle":1466,"status":564,"phases":1467,"primaryCompletion":801,"completion":1468,"start":1469,"enrollment":11,"conditions":1470,"interventions":1473},"NCT01586091","Safety Study of Levocetirizine and Fexofenadine",[90],"2012-02","2011-02",[1471,651,1472],"Pruritus","Allergic Rhinitis",[1452,1474],"Fexofenadine 60 Mg Oral",{"trials":1476,"activeCount":98},[],{"intervention":1474,"totalTrials":94,"cells":1478},{"EARLY_PHASE1":1479,"PHASE1":1481,"PHASE2":1483,"PHASE3":1485,"PHASE4":1487,"NA":1493},{"trials":1480,"activeCount":98},[],{"trials":1482,"activeCount":98},[],{"trials":1484,"activeCount":98},[],{"trials":1486,"activeCount":98},[],{"trials":1488,"activeCount":98},[1489],{"nctId":1465,"briefTitle":1466,"status":564,"phases":1490,"primaryCompletion":801,"completion":1468,"start":1469,"enrollment":11,"conditions":1491,"interventions":1492},[90],[1471,651,1472],[1452,1474],{"trials":1494,"activeCount":98},[],{"intervention":1496,"totalTrials":94,"cells":1497},"recombinant human Growth Hormone",{"EARLY_PHASE1":1498,"PHASE1":1500,"PHASE2":1502,"PHASE3":1504,"PHASE4":1506,"NA":1517},{"trials":1499,"activeCount":98},[],{"trials":1501,"activeCount":98},[],{"trials":1503,"activeCount":98},[],{"trials":1505,"activeCount":98},[],{"trials":1507,"activeCount":98},[1508],{"nctId":1509,"briefTitle":1510,"status":564,"phases":1511,"primaryCompletion":1008,"completion":1008,"start":1512,"enrollment":1513,"conditions":1514,"interventions":1516},"NCT00929799","Growth Hormone and Glucose Metabolism",[90],"2003-11",6,[1515],"Growth Hormone Deficiency",[1496],{"trials":1518,"activeCount":98},[],{"intervention":1520,"totalTrials":94,"cells":1521},"diclophenac",{"EARLY_PHASE1":1522,"PHASE1":1524,"PHASE2":1526,"PHASE3":1528,"PHASE4":1530,"NA":1541},{"trials":1523,"activeCount":98},[],{"trials":1525,"activeCount":98},[],{"trials":1527,"activeCount":98},[],{"trials":1529,"activeCount":98},[],{"trials":1531,"activeCount":98},[1532],{"nctId":1533,"briefTitle":1534,"status":564,"phases":1535,"primaryCompletion":1536,"completion":1536,"start":1537,"enrollment":1538,"conditions":1539,"interventions":1540},"NCT00715091","Effects of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) on RAdiographic Damage in Ankylosing Spondylitis",[90],"2013-12","2008-09",180,[33],[1520,1520],{"trials":1542,"activeCount":98},[],{"intervention":1544,"totalTrials":94,"cells":1545},"Sirolimus",{"EARLY_PHASE1":1546,"PHASE1":1548,"PHASE2":1550,"PHASE3":1552,"PHASE4":1554,"NA":1570},{"trials":1547,"activeCount":98},[],{"trials":1549,"activeCount":98},[],{"trials":1551,"activeCount":98},[],{"trials":1553,"activeCount":98},[],{"trials":1555,"activeCount":98},[1556],{"nctId":1557,"briefTitle":1558,"status":201,"phases":1559,"primaryCompletion":1560,"completion":1560,"start":1561,"enrollment":1562,"conditions":1563,"interventions":1565},"NCT00866684","Prevention of Skin Cancer in High Risk Patients After Conversion to a Sirolimus-based Immunosuppressive Protocol",[90],"2011-04-19","2007-01-01",44,[1564],"Skin Cancer",[1544,1566,1567,1568,1569],"Azathioprine","Mycophenolate","Ciclosporin","Tacrolimus",{"trials":1571,"activeCount":98},[],{"intervention":1566,"totalTrials":94,"cells":1573},{"EARLY_PHASE1":1574,"PHASE1":1576,"PHASE2":1578,"PHASE3":1580,"PHASE4":1582,"NA":1588},{"trials":1575,"activeCount":98},[],{"trials":1577,"activeCount":98},[],{"trials":1579,"activeCount":98},[],{"trials":1581,"activeCount":98},[],{"trials":1583,"activeCount":98},[1584],{"nctId":1557,"briefTitle":1558,"status":201,"phases":1585,"primaryCompletion":1560,"completion":1560,"start":1561,"enrollment":1562,"conditions":1586,"interventions":1587},[90],[1564],[1544,1566,1567,1568,1569],{"trials":1589,"activeCount":98},[],{"intervention":1567,"totalTrials":94,"cells":1591},{"EARLY_PHASE1":1592,"PHASE1":1594,"PHASE2":1596,"PHASE3":1598,"PHASE4":1600,"NA":1606},{"trials":1593,"activeCount":98},[],{"trials":1595,"activeCount":98},[],{"trials":1597,"activeCount":98},[],{"trials":1599,"activeCount":98},[],{"trials":1601,"activeCount":98},[1602],{"nctId":1557,"briefTitle":1558,"status":201,"phases":1603,"primaryCompletion":1560,"completion":1560,"start":1561,"enrollment":1562,"conditions":1604,"interventions":1605},[90],[1564],[1544,1566,1567,1568,1569],{"trials":1607,"activeCount":98},[],{"intervention":1568,"totalTrials":94,"cells":1609},{"EARLY_PHASE1":1610,"PHASE1":1612,"PHASE2":1614,"PHASE3":1616,"PHASE4":1618,"NA":1624},{"trials":1611,"activeCount":98},[],{"trials":1613,"activeCount":98},[],{"trials":1615,"activeCount":98},[],{"trials":1617,"activeCount":98},[],{"trials":1619,"activeCount":98},[1620],{"nctId":1557,"briefTitle":1558,"status":201,"phases":1621,"primaryCompletion":1560,"completion":1560,"start":1561,"enrollment":1562,"conditions":1622,"interventions":1623},[90],[1564],[1544,1566,1567,1568,1569],{"trials":1625,"activeCount":98},[],{"intervention":1569,"totalTrials":94,"cells":1627},{"EARLY_PHASE1":1628,"PHASE1":1630,"PHASE2":1632,"PHASE3":1634,"PHASE4":1636,"NA":1642},{"trials":1629,"activeCount":98},[],{"trials":1631,"activeCount":98},[],{"trials":1633,"activeCount":98},[],{"trials":1635,"activeCount":98},[],{"trials":1637,"activeCount":98},[1638],{"nctId":1557,"briefTitle":1558,"status":201,"phases":1639,"primaryCompletion":1560,"completion":1560,"start":1561,"enrollment":1562,"conditions":1640,"interventions":1641},[90],[1564],[1544,1566,1567,1568,1569],{"trials":1643,"activeCount":98},[],{"intervention":1645,"totalTrials":94,"cells":1646},"Golimumab",{"EARLY_PHASE1":1647,"PHASE1":1649,"PHASE2":1651,"PHASE3":1653,"PHASE4":1655,"NA":1667},{"trials":1648,"activeCount":98},[],{"trials":1650,"activeCount":98},[],{"trials":1652,"activeCount":98},[],{"trials":1654,"activeCount":98},[],{"trials":1656,"activeCount":98},[1657],{"nctId":1658,"briefTitle":1659,"status":564,"phases":1660,"primaryCompletion":1661,"completion":1661,"start":1662,"enrollment":1663,"conditions":1664,"interventions":1665},"NCT02758782","NSAIDs Added to Anti-TNF Therapy Versus Anti-TNF Therapy Alone on Progression of Structural Damage in Ankylosing Spondylitis",[90],"2021-01","2016-09",156,[33],[1645,1666],"Celecoxib",{"trials":1668,"activeCount":98},[],{"intervention":1666,"totalTrials":94,"cells":1670},{"EARLY_PHASE1":1671,"PHASE1":1673,"PHASE2":1675,"PHASE3":1677,"PHASE4":1679,"NA":1685},{"trials":1672,"activeCount":98},[],{"trials":1674,"activeCount":98},[],{"trials":1676,"activeCount":98},[],{"trials":1678,"activeCount":98},[],{"trials":1680,"activeCount":98},[1681],{"nctId":1658,"briefTitle":1659,"status":564,"phases":1682,"primaryCompletion":1661,"completion":1661,"start":1662,"enrollment":1663,"conditions":1683,"interventions":1684},[90],[33],[1645,1666],{"trials":1686,"activeCount":98},[],{"intervention":1688,"totalTrials":94,"cells":1689},"Alefacept",{"EARLY_PHASE1":1690,"PHASE1":1692,"PHASE2":1694,"PHASE3":1696,"PHASE4":1698,"NA":1708},{"trials":1691,"activeCount":98},[],{"trials":1693,"activeCount":98},[],{"trials":1695,"activeCount":98},[],{"trials":1697,"activeCount":98},[],{"trials":1699,"activeCount":98},[1700],{"nctId":1701,"briefTitle":1702,"status":564,"phases":1703,"primaryCompletion":1419,"completion":1419,"start":1704,"enrollment":240,"conditions":1705,"interventions":1707},"NCT00794807","Safety and Tolerability of Repeat Courses of IM Alefacept",[90],"2004-02",[1706],"Chronic Plaque Psoriasis",[1688],{"trials":1709,"activeCount":98},[],{"intervention":1711,"totalTrials":551,"cells":1712},"Epigallocatechin-Gallate",{"EARLY_PHASE1":1713,"PHASE1":1715,"PHASE2":1717,"PHASE3":1729,"PHASE4":1749,"NA":1751},{"trials":1714,"activeCount":98},[],{"trials":1716,"activeCount":98},[],{"trials":1718,"activeCount":98},[1719],{"nctId":1720,"briefTitle":1721,"status":564,"phases":1722,"primaryCompletion":1723,"completion":1723,"start":648,"enrollment":1724,"conditions":1725,"interventions":1727},"NCT00525668","Sunphenon Epigallocatechin-gallate (EGCg) in Relapsing-remitting Multiple Sclerosis (SuniMS Study)",[87,88],"2012-11",120,[1726],"Relapsing-remitting Multiple Sclerosis",[1728],"epigallocatechin-gallate",{"trials":1730,"activeCount":98},[1731,1740],{"nctId":1732,"briefTitle":1733,"status":564,"phases":1734,"primaryCompletion":1735,"completion":1735,"start":1736,"enrollment":661,"conditions":1737,"interventions":1739},"NCT01183767","Sunphenon Epigallocatechin-Gallate (EGCg) in Duchenne Muscular Dystrophy",[88,89],"2018-09-06","2010-12-30",[1738],"Duchenne Muscular Dystrophy",[1711],{"nctId":1741,"briefTitle":1742,"status":564,"phases":1743,"primaryCompletion":1744,"completion":1744,"start":1745,"enrollment":1746,"conditions":1747,"interventions":1748},"NCT00951834","Sunphenon EGCg (Epigallocatechin-Gallate) in the Early Stage of Alzheimer´s Disease",[88,89],"2015-02","2009-10",21,[898],[1711],{"trials":1750,"activeCount":98},[],{"trials":1752,"activeCount":98},[],{"intervention":1754,"totalTrials":249,"cells":1755},"Paclitaxel",{"EARLY_PHASE1":1756,"PHASE1":1758,"PHASE2":1760,"PHASE3":1773,"PHASE4":1788,"NA":1790},{"trials":1757,"activeCount":98},[],{"trials":1759,"activeCount":98},[],{"trials":1761,"activeCount":98},[1762],{"nctId":1763,"briefTitle":1764,"status":214,"phases":1765,"completion":1766,"start":1767,"enrollment":473,"conditions":1768,"interventions":1770},"NCT00168883","Study for Patients With Non Small Cell Lung Cancer (NSCLC)",[88],"2006-12","2002-10",[1769],"Carcinoma, Non-Small-Cell Lung",[1771,1754,1772],"Carboplatin","Vinorelbine",{"trials":1774,"activeCount":98},[1775],{"nctId":1776,"briefTitle":1777,"status":214,"phases":1778,"primaryCompletion":1779,"completion":1780,"start":1781,"enrollment":1782,"conditions":1783,"interventions":1785},"NCT02422563","NeoAdjuvant Chemotherapy Followed by Radical Hysterectomy (OP) Versus Primary Chemo-RADiation in Cervical Cancer FIGO Stage IB2 and IIB",[89],"2020-10","2025-10","2015-10",534,[1784],"Cervical Cancer",[1786,1754,1771,1787],"Cisplatin","Ifosfamide",{"trials":1789,"activeCount":98},[],{"trials":1791,"activeCount":98},[],{"intervention":1771,"totalTrials":249,"cells":1793},{"EARLY_PHASE1":1794,"PHASE1":1796,"PHASE2":1798,"PHASE3":1804,"PHASE4":1810,"NA":1812},{"trials":1795,"activeCount":98},[],{"trials":1797,"activeCount":98},[],{"trials":1799,"activeCount":98},[1800],{"nctId":1763,"briefTitle":1764,"status":214,"phases":1801,"completion":1766,"start":1767,"enrollment":473,"conditions":1802,"interventions":1803},[88],[1769],[1771,1754,1772],{"trials":1805,"activeCount":98},[1806],{"nctId":1776,"briefTitle":1777,"status":214,"phases":1807,"primaryCompletion":1779,"completion":1780,"start":1781,"enrollment":1782,"conditions":1808,"interventions":1809},[89],[1784],[1786,1754,1771,1787],{"trials":1811,"activeCount":98},[],{"trials":1813,"activeCount":98},[],{"intervention":1815,"totalTrials":249,"cells":1816},"Levetiracetam",{"EARLY_PHASE1":1817,"PHASE1":1819,"PHASE2":1821,"PHASE3":1823,"PHASE4":1846,"NA":1848},{"trials":1818,"activeCount":98},[],{"trials":1820,"activeCount":98},[],{"trials":1822,"activeCount":98},[],{"trials":1824,"activeCount":98},[1825,1833],{"nctId":1826,"briefTitle":1827,"status":564,"phases":1828,"primaryCompletion":1393,"completion":648,"start":1829,"enrollment":1724,"conditions":1830,"interventions":1832},"NCT00146471","Efficacy and Safety of Levetiracetam in the Inpatient Treatment of Alcohol Withdrawal Syndrome",[89],"2006-01",[1831],"Alcohol Withdrawal Syndrome",[1815],{"nctId":1834,"briefTitle":1835,"status":564,"phases":1836,"primaryCompletion":1837,"completion":1838,"start":1839,"enrollment":1840,"conditions":1841,"interventions":1844},"NCT00758277","Efficacy and Safety of Levetiracetam in Prevention of Alcohol Relapse in Recently Detoxified Alcohol Dependent Patients",[89],"2009-07","2009-12","2007-05",201,[1842,1843],"Alcohol Dependence","Alcoholic Relapse",[1845],"levetiracetam",{"trials":1847,"activeCount":98},[],{"trials":1849,"activeCount":98},[],{"intervention":1851,"totalTrials":249,"cells":1852},"Bilastine",{"EARLY_PHASE1":1853,"PHASE1":1855,"PHASE2":1857,"PHASE3":1859,"PHASE4":1880,"NA":1882},{"trials":1854,"activeCount":98},[],{"trials":1856,"activeCount":98},[],{"trials":1858,"activeCount":98},[],{"trials":1860,"activeCount":98},[1861,1871],{"nctId":1862,"briefTitle":1863,"status":564,"phases":1864,"primaryCompletion":1865,"completion":1866,"start":1867,"enrollment":240,"conditions":1868,"interventions":1870},"NCT01271075","Bilastine Updosing - Characterization of Underlying Mechanisms",[88,89],"2011-08","2011-12","2010-09",[1869],"Cold Contact Urticaria",[1851,1851],{"nctId":1872,"briefTitle":1873,"status":564,"phases":1874,"primaryCompletion":1875,"completion":1875,"start":1876,"enrollment":983,"conditions":1877,"interventions":1878},"NCT02213367","Bilastine Updosing in Chronic Spontaneous Urticaria",[89],"2016-03","2014-07",[651],[1851,1851,1879],"Bilastin",{"trials":1881,"activeCount":98},[],{"trials":1883,"activeCount":98},[],{"intervention":1885,"totalTrials":94,"cells":1886},"minoxidil",{"EARLY_PHASE1":1887,"PHASE1":1889,"PHASE2":1891,"PHASE3":1893,"PHASE4":1907,"NA":1909},{"trials":1888,"activeCount":98},[],{"trials":1890,"activeCount":98},[],{"trials":1892,"activeCount":98},[],{"trials":1894,"activeCount":98},[1895],{"nctId":1896,"briefTitle":1897,"status":564,"phases":1898,"primaryCompletion":1899,"completion":1900,"start":1901,"enrollment":1902,"conditions":1903,"interventions":1906},"NCT00958750","Efficacy and Safety Study to Compare Two Minoxidil Formulations on Women With Androgenetic Alopecia",[89],"2009-02","2009-06","2008-06",113,[1904,1905],"Androgenetic Alopecia","Female Pattern Hair Loss",[1885],{"trials":1908,"activeCount":98},[],{"trials":1910,"activeCount":98},[],{"intervention":1912,"totalTrials":94,"cells":1913},"Nicotinic acid",{"EARLY_PHASE1":1914,"PHASE1":1916,"PHASE2":1918,"PHASE3":1920,"PHASE4":1931,"NA":1933},{"trials":1915,"activeCount":98},[],{"trials":1917,"activeCount":98},[],{"trials":1919,"activeCount":98},[],{"trials":1921,"activeCount":98},[1922],{"nctId":1923,"briefTitle":1924,"status":214,"phases":1925,"primaryCompletion":1838,"completion":1926,"start":577,"enrollment":1927,"conditions":1928,"interventions":1930},"NCT00633698","Evaluation of the Effect of NICOtinic Acid (Niacin) on Elevated Lipoprotein(a) Levels (NICOLa Study)",[89],"2010-03",150,[1929],"Elevated Lipoprotein(a) Levels",[1912],{"trials":1932,"activeCount":98},[],{"trials":1934,"activeCount":98},[],{"intervention":1786,"totalTrials":94,"cells":1936},{"EARLY_PHASE1":1937,"PHASE1":1939,"PHASE2":1941,"PHASE3":1943,"PHASE4":1949,"NA":1951},{"trials":1938,"activeCount":98},[],{"trials":1940,"activeCount":98},[],{"trials":1942,"activeCount":98},[],{"trials":1944,"activeCount":98},[1945],{"nctId":1776,"briefTitle":1777,"status":214,"phases":1946,"primaryCompletion":1779,"completion":1780,"start":1781,"enrollment":1782,"conditions":1947,"interventions":1948},[89],[1784],[1786,1754,1771,1787],{"trials":1950,"activeCount":98},[],{"trials":1952,"activeCount":98},[],{"intervention":1787,"totalTrials":94,"cells":1954},{"EARLY_PHASE1":1955,"PHASE1":1957,"PHASE2":1959,"PHASE3":1961,"PHASE4":1967,"NA":1969},{"trials":1956,"activeCount":98},[],{"trials":1958,"activeCount":98},[],{"trials":1960,"activeCount":98},[],{"trials":1962,"activeCount":98},[1963],{"nctId":1776,"briefTitle":1777,"status":214,"phases":1964,"primaryCompletion":1779,"completion":1780,"start":1781,"enrollment":1782,"conditions":1965,"interventions":1966},[89],[1784],[1786,1754,1771,1787],{"trials":1968,"activeCount":98},[],{"trials":1970,"activeCount":98},[],{"intervention":1972,"totalTrials":94,"cells":1973},"Glucagon hydrochloride",{"EARLY_PHASE1":1974,"PHASE1":1976,"PHASE2":1978,"PHASE3":1980,"PHASE4":1994,"NA":1996},{"trials":1975,"activeCount":98},[],{"trials":1977,"activeCount":98},[],{"trials":1979,"activeCount":98},[],{"trials":1981,"activeCount":98},[1982],{"nctId":1983,"briefTitle":1984,"status":214,"phases":1985,"primaryCompletion":577,"completion":1838,"start":1986,"enrollment":1987,"conditions":1988,"interventions":1992},"NCT00929812","Glucagon Modulation of Ghrelin Secretion",[89],"2006-06",38,[1989,1990,1991],"Healthy Subjects","Obesity","Diabetes Mellitus, Type 1",[1972,1993],"NaCl 0.9%",{"trials":1995,"activeCount":98},[],{"trials":1997,"activeCount":98},[],{"intervention":1993,"totalTrials":94,"cells":1999},{"EARLY_PHASE1":2000,"PHASE1":2002,"PHASE2":2004,"PHASE3":2006,"PHASE4":2012,"NA":2014},{"trials":2001,"activeCount":98},[],{"trials":2003,"activeCount":98},[],{"trials":2005,"activeCount":98},[],{"trials":2007,"activeCount":98},[2008],{"nctId":1983,"briefTitle":1984,"status":214,"phases":2009,"primaryCompletion":577,"completion":1838,"start":1986,"enrollment":1987,"conditions":2010,"interventions":2011},[89],[1989,1990,1991],[1972,1993],{"trials":2013,"activeCount":98},[],{"trials":2015,"activeCount":98},[],{"intervention":2017,"totalTrials":94,"cells":2018},"Peginterferon alfa-2a",{"EARLY_PHASE1":2019,"PHASE1":2021,"PHASE2":2023,"PHASE3":2025,"PHASE4":2036,"NA":2038},{"trials":2020,"activeCount":98},[],{"trials":2022,"activeCount":98},[],{"trials":2024,"activeCount":98},[],{"trials":2026,"activeCount":98},[2027],{"nctId":2028,"briefTitle":2029,"status":564,"phases":2030,"primaryCompletion":1537,"completion":1537,"start":1059,"enrollment":2031,"conditions":2032,"interventions":2033},"NCT00136318","Escitalopram for the Prevention of PEGASYS-associated Depression in Hepatitis C Virus-infected Patients",[89],208,[31],[2034,2017,2035],"Escitalopram","Ribavirin",{"trials":2037,"activeCount":98},[],{"trials":2039,"activeCount":98},[],{"intervention":2035,"totalTrials":94,"cells":2041},{"EARLY_PHASE1":2042,"PHASE1":2044,"PHASE2":2046,"PHASE3":2048,"PHASE4":2054,"NA":2056},{"trials":2043,"activeCount":98},[],{"trials":2045,"activeCount":98},[],{"trials":2047,"activeCount":98},[],{"trials":2049,"activeCount":98},[2050],{"nctId":2028,"briefTitle":2029,"status":564,"phases":2051,"primaryCompletion":1537,"completion":1537,"start":1059,"enrollment":2031,"conditions":2052,"interventions":2053},[89],[31],[2034,2017,2035],{"trials":2055,"activeCount":98},[],{"trials":2057,"activeCount":98},[],{"intervention":2059,"totalTrials":94,"cells":2060},"10 mg Rupatadine on demand",{"EARLY_PHASE1":2061,"PHASE1":2063,"PHASE2":2065,"PHASE3":2067,"PHASE4":2081,"NA":2083},{"trials":2062,"activeCount":98},[],{"trials":2064,"activeCount":98},[],{"trials":2066,"activeCount":98},[],{"trials":2068,"activeCount":98},[2069],{"nctId":2070,"briefTitle":2071,"status":201,"phases":2072,"primaryCompletion":2073,"completion":2074,"start":2075,"enrollment":2076,"conditions":2077,"interventions":2078},"NCT02358265","Chronic Urticaria - Long Term Assessment of Effects of Rupatadine",[89],"2017-11-20","2018-06-15","2014-12",192,[651],[2059,2079,2080,2059],"10 mg Rupatadine","20 mg Rupatadine",{"trials":2082,"activeCount":98},[],{"trials":2084,"activeCount":98},[],{"intervention":2079,"totalTrials":94,"cells":2086},{"EARLY_PHASE1":2087,"PHASE1":2089,"PHASE2":2091,"PHASE3":2093,"PHASE4":2099,"NA":2101},{"trials":2088,"activeCount":98},[],{"trials":2090,"activeCount":98},[],{"trials":2092,"activeCount":98},[],{"trials":2094,"activeCount":98},[2095],{"nctId":2070,"briefTitle":2071,"status":201,"phases":2096,"primaryCompletion":2073,"completion":2074,"start":2075,"enrollment":2076,"conditions":2097,"interventions":2098},[89],[651],[2059,2079,2080,2059],{"trials":2100,"activeCount":98},[],{"trials":2102,"activeCount":98},[],{"intervention":2080,"totalTrials":94,"cells":2104},{"EARLY_PHASE1":2105,"PHASE1":2107,"PHASE2":2109,"PHASE3":2111,"PHASE4":2117,"NA":2119},{"trials":2106,"activeCount":98},[],{"trials":2108,"activeCount":98},[],{"trials":2110,"activeCount":98},[],{"trials":2112,"activeCount":98},[2113],{"nctId":2070,"briefTitle":2071,"status":201,"phases":2114,"primaryCompletion":2073,"completion":2074,"start":2075,"enrollment":2076,"conditions":2115,"interventions":2116},[89],[651],[2059,2079,2080,2059],{"trials":2118,"activeCount":98},[],{"trials":2120,"activeCount":98},[],{"intervention":2122,"totalTrials":94,"cells":2123},"homeopathic q-potencies",{"EARLY_PHASE1":2124,"PHASE1":2126,"PHASE2":2128,"PHASE3":2130,"PHASE4":2141,"NA":2143},{"trials":2125,"activeCount":98},[],{"trials":2127,"activeCount":98},[],{"trials":2129,"activeCount":98},[],{"trials":2131,"activeCount":98},[2132],{"nctId":2133,"briefTitle":2134,"status":201,"phases":2135,"primaryCompletion":2136,"completion":2136,"start":2137,"enrollment":1562,"conditions":2138,"interventions":2140},"NCT01178255","Efficacy and Safety of Homeopathy for Moderate Depression (Acute Phase)",[89],"2011-07","2010-08",[2139],"Major Depression",[2122],{"trials":2142,"activeCount":98},[],{"trials":2144,"activeCount":98},[],{"intervention":2146,"totalTrials":94,"cells":2147},"Experimental: Spironolactone",{"EARLY_PHASE1":2148,"PHASE1":2150,"PHASE2":2152,"PHASE3":2154,"PHASE4":2167,"NA":2169},{"trials":2149,"activeCount":98},[],{"trials":2151,"activeCount":98},[],{"trials":2153,"activeCount":98},[],{"trials":2155,"activeCount":98},[2156],{"nctId":2157,"briefTitle":2158,"status":201,"phases":2159,"primaryCompletion":2160,"completion":2160,"start":2161,"enrollment":2162,"conditions":2163,"interventions":2166},"NCT04727073","Spironolactone in the Treatment of Heart Failure",[89],"2024-10-01","2018-11-01",743,[2164,2165],"Heart Failure with Mid-range Ejection Fraction","Heart Failure with Preserved Ejection Fraction",[2146],{"trials":2168,"activeCount":98},[],{"trials":2170,"activeCount":98},[],{"intervention":2172,"totalTrials":94,"cells":2173},"Glandosane",{"EARLY_PHASE1":2174,"PHASE1":2176,"PHASE2":2178,"PHASE3":2180,"PHASE4":2193,"NA":2195},{"trials":2175,"activeCount":98},[],{"trials":2177,"activeCount":98},[],{"trials":2179,"activeCount":98},[],{"trials":2181,"activeCount":98},[2182],{"nctId":2183,"briefTitle":2184,"status":201,"phases":2185,"primaryCompletion":2186,"completion":2187,"start":2188,"enrollment":2189,"conditions":2190,"interventions":2192},"NCT01165970","Effect of Saliva Substitutes on Dental Hard Tissues in Situ",[88,89],"2012-03","2012-12","2009-01",19,[2191],"Hyposalivation",[2172],{"trials":2194,"activeCount":98},[],{"trials":2196,"activeCount":98},[],{"intervention":2198,"totalTrials":94,"cells":2199},"Irinotecan",{"EARLY_PHASE1":2200,"PHASE1":2202,"PHASE2":2204,"PHASE3":2206,"PHASE4":2216,"NA":2218},{"trials":2201,"activeCount":98},[],{"trials":2203,"activeCount":98},[],{"trials":2205,"activeCount":98},[],{"trials":2207,"activeCount":98},[2208],{"nctId":2209,"briefTitle":2210,"status":564,"phases":2211,"start":1767,"enrollment":1562,"conditions":2212,"interventions":2215},"NCT00144378","Irinotecan Versus Only Best Supportive Care for Gastric Cancer",[89],[2213,2214],"Stomach Neoplasm","Neoplasm Metastasis",[2198],{"trials":2217,"activeCount":98},[],{"trials":2219,"activeCount":98},[],{"intervention":2221,"totalTrials":94,"cells":2222},"Carboplatin plus Irinotecan vs Carboplatin plus Etoposide",{"EARLY_PHASE1":2223,"PHASE1":2225,"PHASE2":2227,"PHASE3":2229,"PHASE4":2240,"NA":2242},{"trials":2224,"activeCount":98},[],{"trials":2226,"activeCount":98},[],{"trials":2228,"activeCount":98},[],{"trials":2230,"activeCount":98},[2231],{"nctId":2232,"briefTitle":2233,"status":214,"phases":2234,"completion":1766,"start":2235,"enrollment":2236,"conditions":2237,"interventions":2239},"NCT00168896","A Study for Small Cell Lung Cancer (SCLC) in Extensive Disease Stage",[88,89],"2001-10",286,[2238],"Small Cell Lung Cancer",[2221],{"trials":2241,"activeCount":98},[],{"trials":2243,"activeCount":98},[],{"intervention":2245,"totalTrials":94,"cells":2246},"Adalimumab 40 mg sc every other week",{"EARLY_PHASE1":2247,"PHASE1":2249,"PHASE2":2251,"PHASE3":2253,"PHASE4":2263,"NA":2265},{"trials":2248,"activeCount":98},[],{"trials":2250,"activeCount":98},[],{"trials":2252,"activeCount":98},[],{"trials":2254,"activeCount":98},[2255],{"nctId":2256,"briefTitle":2257,"status":214,"phases":2258,"completion":589,"start":2259,"enrollment":2260,"conditions":2261,"interventions":2262},"NCT00235105","D2E7-Early AS",[88,89],"2005-03",46,[33],[2245],{"trials":2264,"activeCount":98},[],{"trials":2266,"activeCount":98},[],{"intervention":2268,"totalTrials":94,"cells":2269},"prednisolone",{"EARLY_PHASE1":2270,"PHASE1":2272,"PHASE2":2274,"PHASE3":2276,"PHASE4":2287,"NA":2289},{"trials":2271,"activeCount":98},[],{"trials":2273,"activeCount":98},[],{"trials":2275,"activeCount":98},[],{"trials":2277,"activeCount":98},[2278],{"nctId":2279,"briefTitle":2280,"status":214,"phases":2281,"completion":2282,"start":2283,"enrollment":2284,"conditions":2285,"interventions":2286},"NCT00244166","Prednisolone in Active Ankylosing Spondylitis (AS)",[88,89],"2008-08","2002-05",75,[33],[2268],{"trials":2288,"activeCount":98},[],{"trials":2290,"activeCount":98},[],{"intervention":2292,"totalTrials":94,"cells":2293},"Baclofen",{"EARLY_PHASE1":2294,"PHASE1":2296,"PHASE2":2298,"PHASE3":2300,"PHASE4":2310,"NA":2312},{"trials":2295,"activeCount":98},[],{"trials":2297,"activeCount":98},[],{"trials":2299,"activeCount":98},[],{"trials":2301,"activeCount":98},[2302],{"nctId":2303,"briefTitle":2304,"status":564,"phases":2305,"primaryCompletion":2306,"completion":2306,"start":1469,"enrollment":2307,"conditions":2308,"interventions":2309},"NCT01266655","Baclofen for the Treatment of Alcohol Dependence",[88,89],"2014-05",56,[1842],[2292],{"trials":2311,"activeCount":98},[],{"trials":2313,"activeCount":98},[],{"intervention":2315,"totalTrials":94,"cells":2316},"Levofloxacin",{"EARLY_PHASE1":2317,"PHASE1":2319,"PHASE2":2321,"PHASE3":2323,"PHASE4":2333,"NA":2335},{"trials":2318,"activeCount":98},[],{"trials":2320,"activeCount":98},[],{"trials":2322,"activeCount":98},[],{"trials":2324,"activeCount":98},[2325],{"nctId":2326,"briefTitle":2327,"status":214,"phases":2328,"conditions":2329,"interventions":2332},"NCT00215007","Trial of Levofloxacin as Prophylaxis After Allogeneic Stem Cell Transplantation (SCT)",[88,89],[2330,2331],"Malignancy","Allogeneic Stem Cell Transplantation",[2315],{"trials":2334,"activeCount":98},[],{"trials":2336,"activeCount":98},[],{"intervention":2338,"totalTrials":94,"cells":2339},"Preloading before TAVI",{"EARLY_PHASE1":2340,"PHASE1":2342,"PHASE2":2344,"PHASE3":2346,"PHASE4":2362,"NA":2364},{"trials":2341,"activeCount":98},[],{"trials":2343,"activeCount":98},[],{"trials":2345,"activeCount":98},[],{"trials":2347,"activeCount":98},[2348],{"nctId":2349,"briefTitle":2350,"status":214,"phases":2351,"primaryCompletion":2352,"completion":2353,"start":2354,"enrollment":2355,"conditions":2356,"interventions":2360},"NCT03001960","Dual AntiPlatelet Therapies for Prevention of Periinterventional Embolic Events in TAVI",[89],"2018-03","2018-04","2017-03",200,[2357,2358,2359],"Aortic Valve Stenosis","Transcatheter Aortic Valve Replacement","Intracranial Embolism",[2338,2361],"Postloading after TAVI",{"trials":2363,"activeCount":98},[],{"trials":2365,"activeCount":98},[],{"intervention":2361,"totalTrials":94,"cells":2367},{"EARLY_PHASE1":2368,"PHASE1":2370,"PHASE2":2372,"PHASE3":2374,"PHASE4":2380,"NA":2382},{"trials":2369,"activeCount":98},[],{"trials":2371,"activeCount":98},[],{"trials":2373,"activeCount":98},[],{"trials":2375,"activeCount":98},[2376],{"nctId":2349,"briefTitle":2350,"status":214,"phases":2377,"primaryCompletion":2352,"completion":2353,"start":2354,"enrollment":2355,"conditions":2378,"interventions":2379},[89],[2357,2358,2359],[2338,2361],{"trials":2381,"activeCount":98},[],{"trials":2383,"activeCount":98},[],{"intervention":2385,"totalTrials":94,"cells":2386},"Disci\u002FRhus toxicodendron comp.®",{"EARLY_PHASE1":2387,"PHASE1":2389,"PHASE2":2391,"PHASE3":2393,"PHASE4":2402,"NA":2404},{"trials":2388,"activeCount":98},[],{"trials":2390,"activeCount":98},[],{"trials":2392,"activeCount":98},[],{"trials":2394,"activeCount":98},[2395],{"nctId":2396,"briefTitle":2397,"status":564,"phases":2398,"primaryCompletion":2188,"completion":2188,"start":1008,"enrollment":1927,"conditions":2399,"interventions":2401},"NCT00567736","Efficacy of Disci\u002FRhus Toxicodendron Comp.®, in Patients With Chronic Low Back Pain",[89],[2400],"Chronic Low Back Pain",[2385],{"trials":2403,"activeCount":98},[],{"trials":2405,"activeCount":98},[],{"intervention":2407,"totalTrials":94,"cells":2408},"Carbogen",{"EARLY_PHASE1":2409,"PHASE1":2411,"PHASE2":2413,"PHASE3":2415,"PHASE4":2426,"NA":2428},{"trials":2410,"activeCount":98},[],{"trials":2412,"activeCount":98},[],{"trials":2414,"activeCount":98},[],{"trials":2416,"activeCount":98},[2417],{"nctId":2418,"briefTitle":2419,"status":201,"phases":2420,"primaryCompletion":217,"completion":217,"start":2421,"enrollment":2422,"conditions":2423,"interventions":2425},"NCT01370044","Carbon Dioxide (Carbogen) for the Treatment of Febrile Seizures",[88,89],"2012-08",96,[2424],"Febrile Seizure",[2407],{"trials":2427,"activeCount":98},[],{"trials":2429,"activeCount":98},[],{"intervention":2431,"totalTrials":94,"cells":2432},"L-Thyroxine",{"EARLY_PHASE1":2433,"PHASE1":2435,"PHASE2":2437,"PHASE3":2439,"PHASE4":2449,"NA":2451},{"trials":2434,"activeCount":98},[],{"trials":2436,"activeCount":98},[],{"trials":2438,"activeCount":98},[],{"trials":2440,"activeCount":98},[2441],{"nctId":2442,"briefTitle":2443,"status":564,"phases":2444,"primaryCompletion":203,"completion":2282,"start":590,"enrollment":2445,"conditions":2446,"interventions":2448},"NCT01528839","Supraphysiological Doses of Levothyroxine as Adjunctive Therapy in Bipolar Depression",[88,89],74,[2447],"Bipolar Disorder",[2431],{"trials":2450,"activeCount":98},[],{"trials":2452,"activeCount":98},[],{"intervention":2454,"totalTrials":94,"cells":2455},"SR-A + Epratuzumab",{"EARLY_PHASE1":2456,"PHASE1":2458,"PHASE2":2460,"PHASE3":2462,"PHASE4":2473,"NA":2475},{"trials":2457,"activeCount":98},[],{"trials":2459,"activeCount":98},[],{"trials":2461,"activeCount":98},[],{"trials":2463,"activeCount":98},[2464],{"nctId":2465,"briefTitle":2466,"status":564,"phases":2467,"primaryCompletion":2468,"completion":2468,"start":2306,"enrollment":2469,"conditions":2470,"interventions":2471},"NCT01802814","International Study for Treatment of Standard Risk Childhood Relapsed ALL 2010",[89],"2023-07-31",700,[262],[2454,2472],"SR-B + Epratuzumab",{"trials":2474,"activeCount":98},[],{"trials":2476,"activeCount":98},[],{"intervention":2472,"totalTrials":94,"cells":2478},{"EARLY_PHASE1":2479,"PHASE1":2481,"PHASE2":2483,"PHASE3":2485,"PHASE4":2491,"NA":2493},{"trials":2480,"activeCount":98},[],{"trials":2482,"activeCount":98},[],{"trials":2484,"activeCount":98},[],{"trials":2486,"activeCount":98},[2487],{"nctId":2465,"briefTitle":2466,"status":564,"phases":2488,"primaryCompletion":2468,"completion":2468,"start":2306,"enrollment":2469,"conditions":2489,"interventions":2490},[89],[262],[2454,2472],{"trials":2492,"activeCount":98},[],{"trials":2494,"activeCount":98},[],{"intervention":1879,"totalTrials":94,"cells":2496},{"EARLY_PHASE1":2497,"PHASE1":2499,"PHASE2":2501,"PHASE3":2503,"PHASE4":2509,"NA":2511},{"trials":2498,"activeCount":98},[],{"trials":2500,"activeCount":98},[],{"trials":2502,"activeCount":98},[],{"trials":2504,"activeCount":98},[2505],{"nctId":1872,"briefTitle":1873,"status":564,"phases":2506,"primaryCompletion":1875,"completion":1875,"start":1876,"enrollment":983,"conditions":2507,"interventions":2508},[89],[651],[1851,1851,1879],{"trials":2510,"activeCount":98},[],{"trials":2512,"activeCount":98},[],{"intervention":2514,"totalTrials":94,"cells":2515},"Verum arm receiving Gilenya®",{"EARLY_PHASE1":2516,"PHASE1":2518,"PHASE2":2520,"PHASE3":2522,"PHASE4":2533,"NA":2535},{"trials":2517,"activeCount":98},[],{"trials":2519,"activeCount":98},[],{"trials":2521,"activeCount":98},[],{"trials":2523,"activeCount":98},[2524],{"nctId":2525,"briefTitle":2526,"status":201,"phases":2527,"primaryCompletion":2528,"completion":2528,"start":2529,"enrollment":1060,"conditions":2530,"interventions":2531},"NCT01647880","MOdification of VIsual Outcomes After Optic Neuritis in CIS or MS by Gilenya (MOVING Study)",[88,89],"2016-04","2013-07",[23],[2514,2532],"Active Comparator receiving Extavia®",{"trials":2534,"activeCount":98},[],{"trials":2536,"activeCount":98},[],{"intervention":2532,"totalTrials":94,"cells":2538},{"EARLY_PHASE1":2539,"PHASE1":2541,"PHASE2":2543,"PHASE3":2545,"PHASE4":2551,"NA":2553},{"trials":2540,"activeCount":98},[],{"trials":2542,"activeCount":98},[],{"trials":2544,"activeCount":98},[],{"trials":2546,"activeCount":98},[2547],{"nctId":2525,"briefTitle":2526,"status":201,"phases":2548,"primaryCompletion":2528,"completion":2528,"start":2529,"enrollment":1060,"conditions":2549,"interventions":2550},[88,89],[23],[2514,2532],{"trials":2552,"activeCount":98},[],{"trials":2554,"activeCount":98},[],{"intervention":2556,"totalTrials":551,"cells":2557},"Canakinumab",{"EARLY_PHASE1":2558,"PHASE1":2560,"PHASE2":2562,"PHASE3":2593,"PHASE4":2595,"NA":2597},{"trials":2559,"activeCount":98},[],{"trials":2561,"activeCount":98},[],{"trials":2563,"activeCount":98},[2564,2573,2582],{"nctId":2565,"briefTitle":2566,"status":201,"phases":2567,"primaryCompletion":2568,"completion":2568,"start":2569,"enrollment":1244,"conditions":2570,"interventions":2572},"NCT02204293","Canakinumab for Treatment of Adult-onset Still's Disease",[88],"2018-05-05","2012-06-21",[2571],"Adult-Onset Still´s Disease",[2556],{"nctId":2574,"briefTitle":2575,"status":564,"phases":2576,"primaryCompletion":2577,"completion":2578,"start":2136,"enrollment":240,"conditions":2579,"interventions":2581},"NCT01390350","Ilaris® Effects in Schnitzler Syndrome (ILESCH)",[88],"2017-12-21","2018-05",[2580],"Schnitzler Syndrome",[2556],{"nctId":2583,"briefTitle":2584,"status":564,"phases":2585,"primaryCompletion":2586,"completion":1866,"start":2587,"enrollment":29,"conditions":2588,"interventions":2591},"NCT01170936","Ilaris® in Urticarial Vasculitis - Investigation of Treatment Responses",[88],"2011-09","2010-07",[2589,2590],"Urticaria","Vasculitis",[2592],"canakinumab",{"trials":2594,"activeCount":98},[],{"trials":2596,"activeCount":98},[],{"trials":2598,"activeCount":98},[],{"intervention":2600,"totalTrials":249,"cells":2601},"Omalizumab",{"EARLY_PHASE1":2602,"PHASE1":2604,"PHASE2":2606,"PHASE3":2624,"PHASE4":2626,"NA":2628},{"trials":2603,"activeCount":98},[],{"trials":2605,"activeCount":98},[],{"trials":2607,"activeCount":98},[2608,2616],{"nctId":2609,"briefTitle":2610,"status":564,"phases":2611,"primaryCompletion":2075,"completion":2075,"start":2187,"enrollment":2612,"conditions":2613,"interventions":2615},"NCT02169115","Urticaria Facticia Treatment With Omalizumab (UFO)",[88],61,[2614],"Symptomatic Dermographism",[2600,2600],{"nctId":2617,"briefTitle":2618,"status":564,"phases":2619,"primaryCompletion":2075,"completion":1744,"start":2620,"enrollment":2621,"conditions":2622,"interventions":2623},"NCT01580592","Cold Urticaria Treatment With Xolair",[88],"2012-04",31,[1869],[2600,2600],{"trials":2625,"activeCount":98},[],{"trials":2627,"activeCount":98},[],{"trials":2629,"activeCount":98},[],{"intervention":2631,"totalTrials":249,"cells":2632},"WT1 126-134 peptide",{"EARLY_PHASE1":2633,"PHASE1":2635,"PHASE2":2637,"PHASE3":2657,"PHASE4":2659,"NA":2661},{"trials":2634,"activeCount":98},[],{"trials":2636,"activeCount":98},[],{"trials":2638,"activeCount":98},[2639,2649],{"nctId":2640,"briefTitle":2641,"status":214,"phases":2642,"start":2643,"enrollment":2644,"conditions":2645,"interventions":2648},"NCT00153582","WT1 Peptide Vaccination in Acute Myeloid Leukemia (AML)",[88],"2002-04",25,[2646,2647],"Acute Myeloid Leukemia","Myelodysplastic Syndrome",[2631],{"nctId":2650,"briefTitle":2651,"status":214,"phases":2652,"start":2653,"enrollment":2644,"conditions":2654,"interventions":2656},"NCT00153608","WT1 Peptid Vaccination in Carcinomas",[88],"2004-04",[2655],"WT1 Expressing Carcinoma",[2631],{"trials":2658,"activeCount":98},[],{"trials":2660,"activeCount":98},[],{"trials":2662,"activeCount":98},[],{"intervention":2664,"totalTrials":249,"cells":2665},"Etanercept",{"EARLY_PHASE1":2666,"PHASE1":2668,"PHASE2":2670,"PHASE3":2688,"PHASE4":2690,"NA":2692},{"trials":2667,"activeCount":98},[],{"trials":2669,"activeCount":98},[],{"trials":2671,"activeCount":98},[2672,2682],{"nctId":2673,"briefTitle":2674,"status":214,"phases":2675,"primaryCompletion":612,"completion":2676,"start":2677,"enrollment":2678,"conditions":2679,"interventions":2681},"NCT01289730","Etanercept (Enbrel) in Undifferentiated Spondyloarthritis",[88],"2012-05","2002-02",8,[2680],"Spondyloarthritis",[2664],{"nctId":2683,"briefTitle":2684,"status":214,"phases":2685,"primaryCompletion":612,"completion":2676,"start":2677,"enrollment":16,"conditions":2686,"interventions":2687},"NCT01289743","Etanercept (Enbrel) in Ankylosing Spondylitis",[88],[33],[2664],{"trials":2689,"activeCount":98},[],{"trials":2691,"activeCount":98},[],{"trials":2693,"activeCount":98},[],{"intervention":2695,"totalTrials":249,"cells":2696},"Temsirolimus",{"EARLY_PHASE1":2697,"PHASE1":2699,"PHASE2":2701,"PHASE3":2722,"PHASE4":2724,"NA":2726},{"trials":2698,"activeCount":98},[],{"trials":2700,"activeCount":98},[],{"trials":2702,"activeCount":98},[2703,2712],{"nctId":2704,"briefTitle":2705,"status":575,"phases":2706,"primaryCompletion":2620,"completion":2707,"start":802,"enrollment":240,"conditions":2708,"interventions":2710},"NCT01170052","Bendamustine and Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Non-Hodgkin's Lymphoma (NHL)",[87,88],"2014-04",[2709],"Mantle Cell Lymphoma",[2695,2711,2695],"Bendamustine",{"nctId":2713,"briefTitle":2714,"status":214,"phases":2715,"primaryCompletion":1536,"completion":2716,"start":1837,"enrollment":2717,"conditions":2718,"interventions":2720},"NCT00942747","Temsirolimus in Recurrent Primary Central Nervous System (CNS) Lymphoma",[88],"2014-06",37,[2719],"Recurrent or Refractory Primary CNS Lymphoma",[2721],"temsirolimus",{"trials":2723,"activeCount":98},[],{"trials":2725,"activeCount":98},[],{"trials":2727,"activeCount":98},[],{"intervention":2729,"totalTrials":249,"cells":2730},"rilonacept",{"EARLY_PHASE1":2731,"PHASE1":2733,"PHASE2":2735,"PHASE3":2751,"PHASE4":2753,"NA":2755},{"trials":2732,"activeCount":98},[],{"trials":2734,"activeCount":98},[],{"trials":2736,"activeCount":98},[2737,2744],{"nctId":2738,"briefTitle":2739,"status":564,"phases":2740,"primaryCompletion":1867,"completion":1867,"start":2188,"enrollment":29,"conditions":2741,"interventions":2743},"NCT01045772","Safety and Tolerability of Rilonacept in Muckle-Wells Syndrome (MWS) or Schnitzler Syndrome (SchS)",[88],[2742,2580],"Muckle-Wells Syndrome",[2729],{"nctId":2745,"briefTitle":2746,"status":564,"phases":2747,"primaryCompletion":695,"completion":2578,"start":940,"enrollment":240,"conditions":2748,"interventions":2749},"NCT02171416","Cold Contact Urticaria Treatment With Rilonacept",[88],[1869],[2750],"Rilonacept",{"trials":2752,"activeCount":98},[],{"trials":2754,"activeCount":98},[],{"trials":2756,"activeCount":98},[],{"intervention":2758,"totalTrials":249,"cells":2759},"Dupilumab",{"EARLY_PHASE1":2760,"PHASE1":2762,"PHASE2":2764,"PHASE3":2787,"PHASE4":2789,"NA":2791},{"trials":2761,"activeCount":98},[],{"trials":2763,"activeCount":98},[],{"trials":2765,"activeCount":98},[2766,2777],{"nctId":2767,"briefTitle":2768,"status":564,"phases":2769,"primaryCompletion":2770,"completion":2770,"start":2771,"enrollment":2772,"conditions":2773,"interventions":2776},"NCT03749135","Dupilumab in Chronic Spontaneous Urticaria",[88],"2021-07-07","2018-11-12",72,[2774,2775],"Chronic Spontaneous Urticaria","Recurrent Angioedema",[2758],{"nctId":2778,"briefTitle":2779,"status":564,"phases":2780,"primaryCompletion":2781,"completion":2781,"start":2782,"enrollment":2783,"conditions":2784,"interventions":2786},"NCT03749148","Cholinergic Urticaria - Efficacy of Dupilumab",[88],"2023-02-28","2018-12-10",48,[2785],"Cholinergic Urticaria",[2758],{"trials":2788,"activeCount":98},[],{"trials":2790,"activeCount":98},[],{"trials":2792,"activeCount":98},[],{"intervention":2794,"totalTrials":94,"cells":2795},"Lanadelumab",{"EARLY_PHASE1":2796,"PHASE1":2798,"PHASE2":2800,"PHASE3":2810,"PHASE4":2812,"NA":2814},{"trials":2797,"activeCount":98},[],{"trials":2799,"activeCount":98},[],{"trials":2801,"activeCount":98},[2802],{"nctId":2803,"briefTitle":2804,"status":214,"phases":2805,"primaryCompletion":43,"completion":43,"start":2806,"enrollment":190,"conditions":2807,"interventions":2809},"NCT04278885","Lanadelumab in FXII-associated Cold Autoinflammatory Syndrome (FACAS)",[88],"2020-10-05",[2808],"Hereditary Autoinflammatory Disease",[2794],{"trials":2811,"activeCount":98},[],{"trials":2813,"activeCount":98},[],{"trials":2815,"activeCount":98},[],{"intervention":2817,"totalTrials":94,"cells":2818},"Minocycline",{"EARLY_PHASE1":2819,"PHASE1":2821,"PHASE2":2823,"PHASE3":2834,"PHASE4":2836,"NA":2838},{"trials":2820,"activeCount":98},[],{"trials":2822,"activeCount":98},[],{"trials":2824,"activeCount":98},[2825],{"nctId":2826,"briefTitle":2827,"status":564,"phases":2828,"primaryCompletion":2829,"completion":2829,"start":940,"enrollment":2830,"conditions":2831,"interventions":2833},"NCT02456948","Adjunct Minocyline in Treatment-resistant Depression",[88],"2020-08-07",168,[2832],"Major Depressive Disorder",[2817],{"trials":2835,"activeCount":98},[],{"trials":2837,"activeCount":98},[],{"trials":2839,"activeCount":98},[],{"intervention":2841,"totalTrials":94,"cells":2842},"Thalidomide",{"EARLY_PHASE1":2843,"PHASE1":2845,"PHASE2":2847,"PHASE3":2856,"PHASE4":2858,"NA":2860},{"trials":2844,"activeCount":98},[],{"trials":2846,"activeCount":98},[],{"trials":2848,"activeCount":98},[2849],{"nctId":2850,"briefTitle":2851,"status":201,"phases":2852,"completion":2853,"start":1419,"enrollment":568,"conditions":2854,"interventions":2855},"NCT00231140","Pilot-Study of Thalidomide in Amyotrophic Lateral Sclerosis (ALS)",[88],"2006-08",[570],[2841],{"trials":2857,"activeCount":98},[],{"trials":2859,"activeCount":98},[],{"trials":2861,"activeCount":98},[],{"intervention":2863,"totalTrials":94,"cells":2864},"Verum arm receiving Vitamin D oil",{"EARLY_PHASE1":2865,"PHASE1":2867,"PHASE2":2869,"PHASE3":2880,"PHASE4":2882,"NA":2884},{"trials":2866,"activeCount":98},[],{"trials":2868,"activeCount":98},[],{"trials":2870,"activeCount":98},[2871],{"nctId":2872,"briefTitle":2873,"status":201,"phases":2874,"primaryCompletion":2875,"completion":2875,"start":1866,"enrollment":2876,"conditions":2877,"interventions":2878},"NCT01440062","Efficacy of Vitamin D Supplementation in Multiple Sclerosis (EVIDIMS)",[88],"2017-06",55,[23],[2863,2879],"low dose arm receiving neutral oil and 400 IU\u002Fg of Vitamin D every second day",{"trials":2881,"activeCount":98},[],{"trials":2883,"activeCount":98},[],{"trials":2885,"activeCount":98},[],{"intervention":2879,"totalTrials":94,"cells":2887},{"EARLY_PHASE1":2888,"PHASE1":2890,"PHASE2":2892,"PHASE3":2898,"PHASE4":2900,"NA":2902},{"trials":2889,"activeCount":98},[],{"trials":2891,"activeCount":98},[],{"trials":2893,"activeCount":98},[2894],{"nctId":2872,"briefTitle":2873,"status":201,"phases":2895,"primaryCompletion":2875,"completion":2875,"start":1866,"enrollment":2876,"conditions":2896,"interventions":2897},[88],[23],[2863,2879],{"trials":2899,"activeCount":98},[],{"trials":2901,"activeCount":98},[],{"trials":2903,"activeCount":98},[],{"intervention":210,"totalTrials":94,"cells":2905},{"EARLY_PHASE1":2906,"PHASE1":2908,"PHASE2":2910,"PHASE3":2916,"PHASE4":2918,"NA":2920},{"trials":2907,"activeCount":98},[],{"trials":2909,"activeCount":98},[],{"trials":2911,"activeCount":98},[2912],{"nctId":199,"briefTitle":200,"status":201,"phases":2913,"primaryCompletion":203,"completion":204,"start":205,"enrollment":206,"conditions":2914,"interventions":2915},[88],[208],[189,210],{"trials":2917,"activeCount":98},[],{"trials":2919,"activeCount":98},[],{"trials":2921,"activeCount":98},[],{"intervention":2923,"totalTrials":94,"cells":2924},"Alemtuzumab",{"EARLY_PHASE1":2925,"PHASE1":2927,"PHASE2":2929,"PHASE3":2941,"PHASE4":2943,"NA":2945},{"trials":2926,"activeCount":98},[],{"trials":2928,"activeCount":98},[],{"trials":2930,"activeCount":98},[2931],{"nctId":2932,"briefTitle":2933,"status":214,"phases":2934,"primaryCompletion":2935,"completion":2935,"start":2936,"enrollment":2937,"conditions":2938,"interventions":2940},"NCT00337519","Allogeneic Stem Cell Transplantation in Chronic Lymphocytic Leukemia",[88],"2009-04","2003-01",82,[2939],"Chronic Lymphocytic Leukemia",[2923],{"trials":2942,"activeCount":98},[],{"trials":2944,"activeCount":98},[],{"trials":2946,"activeCount":98},[],{"intervention":2948,"totalTrials":94,"cells":2949},"Tofacitinib 5 MG Oral Tablet [Xeljanz]",{"EARLY_PHASE1":2950,"PHASE1":2952,"PHASE2":2954,"PHASE3":2967,"PHASE4":2969,"NA":2971},{"trials":2951,"activeCount":98},[],{"trials":2953,"activeCount":98},[],{"trials":2955,"activeCount":98},[2956],{"nctId":2957,"briefTitle":2958,"status":214,"phases":2959,"primaryCompletion":2960,"completion":2960,"start":2961,"enrollment":473,"conditions":2962,"interventions":2966},"NCT04062695","Tofacitinib for Reduction of Spinal Inflammation in Patients With Psoriatic ArthritiS PresenTing With Axial InvOlvement",[88],"2023-12","2020-08-04",[2963,2964,2965],"Psoriatic Arthritis","Spondylitis","Sacroilitis",[2948],{"trials":2968,"activeCount":98},[],{"trials":2970,"activeCount":98},[],{"trials":2972,"activeCount":98},[],{"intervention":2974,"totalTrials":94,"cells":2975},"Docetaxel, Cisplatin, Capecitabine",{"EARLY_PHASE1":2976,"PHASE1":2978,"PHASE2":2980,"PHASE3":2991,"PHASE4":2993,"NA":2995},{"trials":2977,"activeCount":98},[],{"trials":2979,"activeCount":98},[],{"trials":2981,"activeCount":98},[2982],{"nctId":2983,"briefTitle":2984,"status":214,"phases":2985,"primaryCompletion":2986,"completion":1168,"start":1537,"enrollment":292,"conditions":2987,"interventions":2990},"NCT00865982","Study to Evaluate Safety and Efficacy of Perioperative Chemotherapy With Docetaxel, Cisplatin and Capecitabine (DCX) in Patients With Gastro-esophageal Cancer",[88],"2014-09",[2988,2989],"Gastric Cancer","Esophageal Cancer",[2974],{"trials":2992,"activeCount":98},[],{"trials":2994,"activeCount":98},[],{"trials":2996,"activeCount":98},[],{"intervention":2998,"totalTrials":94,"cells":2999},"DC vaccine",{"EARLY_PHASE1":3000,"PHASE1":3002,"PHASE2":3004,"PHASE3":3014,"PHASE4":3016,"NA":3018},{"trials":3001,"activeCount":98},[],{"trials":3003,"activeCount":98},[],{"trials":3005,"activeCount":98},[3006],{"nctId":3007,"briefTitle":3008,"status":201,"phases":3009,"primaryCompletion":3010,"completion":3010,"start":1876,"enrollment":94,"conditions":3011,"interventions":3013},"NCT02543749","DC Vaccination in CML",[87,88],"2022-07",[3012],"Myeloid Leukemia, Chronic",[2998],{"trials":3015,"activeCount":98},[],{"trials":3017,"activeCount":98},[],{"trials":3019,"activeCount":98},[],{"intervention":3021,"totalTrials":94,"cells":3022},"Voraxaze Injectable Product",{"EARLY_PHASE1":3023,"PHASE1":3025,"PHASE2":3027,"PHASE3":3038,"PHASE4":3040,"NA":3042},{"trials":3024,"activeCount":98},[],{"trials":3026,"activeCount":98},[],{"trials":3028,"activeCount":98},[3029],{"nctId":3030,"briefTitle":3031,"status":564,"phases":3032,"primaryCompletion":3033,"completion":3033,"start":3034,"enrollment":11,"conditions":3035,"interventions":3037},"NCT04841434","A Phase I\u002FII Study to Investigate the Use of VORAXAZE™ As Intended Intervention in Patients with CNSL",[87,88],"2024-12-01","2021-06-01",[3036],"CNS Lymphoma",[3021],{"trials":3039,"activeCount":98},[],{"trials":3041,"activeCount":98},[],{"trials":3043,"activeCount":98},[],{"intervention":3045,"totalTrials":94,"cells":3046},"RAD001 (Everolimus) in combination with carboplatin",{"EARLY_PHASE1":3047,"PHASE1":3049,"PHASE2":3051,"PHASE3":3062,"PHASE4":3064,"NA":3066},{"trials":3048,"activeCount":98},[],{"trials":3050,"activeCount":98},[],{"trials":3052,"activeCount":98},[3053],{"nctId":3054,"briefTitle":3055,"status":214,"phases":3056,"primaryCompletion":3057,"start":1899,"enrollment":3058,"conditions":3059,"interventions":3061},"NCT00930475","Everolimus (RAD001) and Carboplatin in Pretreated Metastatic Breast Cancer",[87,88],"2010-12",54,[3060],"Breast Cancer",[3045,3045],{"trials":3063,"activeCount":98},[],{"trials":3065,"activeCount":98},[],{"trials":3067,"activeCount":98},[],{"intervention":3069,"totalTrials":94,"cells":3070},"Etanercept 25mg",{"EARLY_PHASE1":3071,"PHASE1":3073,"PHASE2":3075,"PHASE3":3085,"PHASE4":3087,"NA":3089},{"trials":3072,"activeCount":98},[],{"trials":3074,"activeCount":98},[],{"trials":3076,"activeCount":98},[3077],{"nctId":3078,"briefTitle":3079,"status":214,"phases":3080,"primaryCompletion":2529,"completion":2529,"start":611,"enrollment":473,"conditions":3081,"interventions":3083},"NCT00844142","Enbrel-Sulfasalazin-Early-Axial Spondyloarthritis (AS)",[88],[3082],"Moderate to Severe Active Axial Spondyloarthritis",[3069,3084],"Sulfasalazine",{"trials":3086,"activeCount":98},[],{"trials":3088,"activeCount":98},[],{"trials":3090,"activeCount":98},[],{"intervention":3084,"totalTrials":94,"cells":3092},{"EARLY_PHASE1":3093,"PHASE1":3095,"PHASE2":3097,"PHASE3":3103,"PHASE4":3105,"NA":3107},{"trials":3094,"activeCount":98},[],{"trials":3096,"activeCount":98},[],{"trials":3098,"activeCount":98},[3099],{"nctId":3078,"briefTitle":3079,"status":214,"phases":3100,"primaryCompletion":2529,"completion":2529,"start":611,"enrollment":473,"conditions":3101,"interventions":3102},[88],[3082],[3069,3084],{"trials":3104,"activeCount":98},[],{"trials":3106,"activeCount":98},[],{"trials":3108,"activeCount":98},[],{"intervention":1772,"totalTrials":94,"cells":3110},{"EARLY_PHASE1":3111,"PHASE1":3113,"PHASE2":3115,"PHASE3":3121,"PHASE4":3123,"NA":3125},{"trials":3112,"activeCount":98},[],{"trials":3114,"activeCount":98},[],{"trials":3116,"activeCount":98},[3117],{"nctId":1763,"briefTitle":1764,"status":214,"phases":3118,"completion":1766,"start":1767,"enrollment":473,"conditions":3119,"interventions":3120},[88],[1769],[1771,1754,1772],{"trials":3122,"activeCount":98},[],{"trials":3124,"activeCount":98},[],{"trials":3126,"activeCount":98},[],{"intervention":3128,"totalTrials":94,"cells":3129},"Tyrosinase, MAGE-3, GnTV",{"EARLY_PHASE1":3130,"PHASE1":3132,"PHASE2":3134,"PHASE3":3144,"PHASE4":3146,"NA":3148},{"trials":3131,"activeCount":98},[],{"trials":3133,"activeCount":98},[],{"trials":3135,"activeCount":98},[3136],{"nctId":3137,"briefTitle":3138,"status":214,"phases":3139,"completion":3140,"start":1033,"enrollment":2644,"conditions":3141,"interventions":3143},"NCT00153569","Multiepitope Peptide Vaccination in Melanoma",[88],"2005-09",[3142],"Metastatic Melanoma",[3128],{"trials":3145,"activeCount":98},[],{"trials":3147,"activeCount":98},[],{"trials":3149,"activeCount":98},[],{"intervention":3151,"totalTrials":94,"cells":3152},"Mutaflor",{"EARLY_PHASE1":3153,"PHASE1":3155,"PHASE2":3157,"PHASE3":3168,"PHASE4":3170,"NA":3172},{"trials":3154,"activeCount":98},[],{"trials":3156,"activeCount":98},[],{"trials":3158,"activeCount":98},[3159],{"nctId":3160,"briefTitle":3161,"status":564,"phases":3162,"primaryCompletion":3163,"completion":1745,"start":1899,"enrollment":3164,"conditions":3165,"interventions":3167},"NCT01013259","Immunomodulation of E.Coli Nissle 1917 in Patients With Grass Pollen Rhinoconjunctivitis",[88],"2009-09",34,[3166],"Rhinoconjunctivitis",[3151],{"trials":3169,"activeCount":98},[],{"trials":3171,"activeCount":98},[],{"trials":3173,"activeCount":98},[],{"intervention":3175,"totalTrials":94,"cells":3176},"Haploidentical transplantation with donor NK cells",{"EARLY_PHASE1":3177,"PHASE1":3179,"PHASE2":3181,"PHASE3":3195,"PHASE4":3197,"NA":3199},{"trials":3178,"activeCount":98},[],{"trials":3180,"activeCount":98},[],{"trials":3182,"activeCount":98},[3183],{"nctId":3184,"briefTitle":3185,"status":214,"phases":3186,"primaryCompletion":3187,"completion":204,"start":3188,"enrollment":983,"conditions":3189,"interventions":3194},"NCT01220544","Haploidentical Transplantation With Early Adoptive Transfer of CD56+CD3- NK Cells",[87,88],"2010-10","2001-07",[3190,3191,3192,3193],"Acute Myeloid Leukemias","Advanced Hematological Malignancies","Indication for Allogeneic Stem Cell Transplantation","no HLA-identical Donor Available",[3175],{"trials":3196,"activeCount":98},[],{"trials":3198,"activeCount":98},[],{"trials":3200,"activeCount":98},[],{"intervention":223,"totalTrials":94,"cells":3202},{"EARLY_PHASE1":3203,"PHASE1":3205,"PHASE2":3207,"PHASE3":3213,"PHASE4":3215,"NA":3217},{"trials":3204,"activeCount":98},[],{"trials":3206,"activeCount":98},[],{"trials":3208,"activeCount":98},[3209],{"nctId":212,"briefTitle":213,"status":214,"phases":3210,"primaryCompletion":216,"completion":217,"start":218,"enrollment":219,"conditions":3211,"interventions":3212},[88],[221],[223,189],{"trials":3214,"activeCount":98},[],{"trials":3216,"activeCount":98},[],{"trials":3218,"activeCount":98},[],{"intervention":3220,"totalTrials":94,"cells":3221},"Ustekinumab",{"EARLY_PHASE1":3222,"PHASE1":3224,"PHASE2":3226,"PHASE3":3237,"PHASE4":3239,"NA":3241},{"trials":3223,"activeCount":98},[],{"trials":3225,"activeCount":98},[],{"trials":3227,"activeCount":98},[3228],{"nctId":3229,"briefTitle":3230,"status":564,"phases":3231,"primaryCompletion":3232,"completion":3233,"start":204,"enrollment":3234,"conditions":3235,"interventions":3236},"NCT01330901","Ustekinumab for the Treatment of Patients With Active Ankylosing Spondylitis",[88],"2013-04","2013-05",22,[33],[3220],{"trials":3238,"activeCount":98},[],{"trials":3240,"activeCount":98},[],{"trials":3242,"activeCount":98},[],{"intervention":3244,"totalTrials":94,"cells":3245},"abatacept",{"EARLY_PHASE1":3246,"PHASE1":3248,"PHASE2":3250,"PHASE3":3258,"PHASE4":3260,"NA":3262},{"trials":3247,"activeCount":98},[],{"trials":3249,"activeCount":98},[],{"trials":3251,"activeCount":98},[3252],{"nctId":3253,"briefTitle":3254,"status":214,"phases":3255,"primaryCompletion":1745,"completion":1838,"start":577,"enrollment":983,"conditions":3256,"interventions":3257},"NCT00558506","Pilot Open Label Clinical Trial With Abatacept in Ankylosing Spondylitis",[88],[33],[3244],{"trials":3259,"activeCount":98},[],{"trials":3261,"activeCount":98},[],{"trials":3263,"activeCount":98},[],{"intervention":3265,"totalTrials":94,"cells":3266},"BX-1",{"EARLY_PHASE1":3267,"PHASE1":3269,"PHASE2":3271,"PHASE3":3283,"PHASE4":3285,"NA":3287},{"trials":3268,"activeCount":98},[],{"trials":3270,"activeCount":98},[],{"trials":3272,"activeCount":98},[3273],{"nctId":3274,"briefTitle":3275,"status":564,"phases":3276,"primaryCompletion":3277,"completion":3277,"start":3278,"enrollment":3279,"conditions":3280,"interventions":3282},"NCT04448808","Treating Nightmares in Posttraumatic Stress Disorder With Dronabinol",[88],"2025-01-02","2020-10-01",170,[3281],"Posttraumatic Stress Disorder",[3265],{"trials":3284,"activeCount":98},[],{"trials":3286,"activeCount":98},[],{"trials":3288,"activeCount":98},[],{"intervention":2711,"totalTrials":94,"cells":3290},{"EARLY_PHASE1":3291,"PHASE1":3293,"PHASE2":3295,"PHASE3":3301,"PHASE4":3303,"NA":3305},{"trials":3292,"activeCount":98},[],{"trials":3294,"activeCount":98},[],{"trials":3296,"activeCount":98},[3297],{"nctId":2704,"briefTitle":2705,"status":575,"phases":3298,"primaryCompletion":2620,"completion":2707,"start":802,"enrollment":240,"conditions":3299,"interventions":3300},[87,88],[2709],[2695,2711,2695],{"trials":3302,"activeCount":98},[],{"trials":3304,"activeCount":98},[],{"trials":3306,"activeCount":98},[],{"intervention":3308,"totalTrials":94,"cells":3309},"Anakinra",{"EARLY_PHASE1":3310,"PHASE1":3312,"PHASE2":3314,"PHASE3":3323,"PHASE4":3325,"NA":3327},{"trials":3311,"activeCount":98},[],{"trials":3313,"activeCount":98},[],{"trials":3315,"activeCount":98},[3316],{"nctId":3317,"briefTitle":3318,"status":564,"phases":3319,"primaryCompletion":3320,"completion":3320,"start":1469,"enrollment":240,"conditions":3321,"interventions":3322},"NCT01277315","Safety and Tolerability of Anakinra in Combination With Riluzol in Amyotrophic Lateral Sclerosis",[88],"2012-06",[570],[3308],{"trials":3324,"activeCount":98},[],{"trials":3326,"activeCount":98},[],{"trials":3328,"activeCount":98},[],{"intervention":3330,"totalTrials":94,"cells":3331},"Niclosamide",{"EARLY_PHASE1":3332,"PHASE1":3334,"PHASE2":3336,"PHASE3":3348,"PHASE4":3350,"NA":3352},{"trials":3333,"activeCount":98},[],{"trials":3335,"activeCount":98},[],{"trials":3337,"activeCount":98},[3338],{"nctId":3339,"briefTitle":3340,"status":214,"phases":3341,"primaryCompletion":3342,"completion":3343,"start":3344,"enrollment":2717,"conditions":3345,"interventions":3347},"NCT02519582","Drug Trial to Investigate the Safety and Efficacy of Niclosamide Tablets in Patients With Metastases of a Colorectal Cancer Progressing After Therapy",[88],"2019-12","2020-08","2015-08",[3346],"Colorectal Cancer",[3330],{"trials":3349,"activeCount":98},[],{"trials":3351,"activeCount":98},[],{"trials":3353,"activeCount":98},[],{"intervention":3355,"totalTrials":94,"cells":3356},"0.125 ng\u002Fkg\u002Fmin Iloprost",{"EARLY_PHASE1":3357,"PHASE1":3359,"PHASE2":3361,"PHASE3":3374,"PHASE4":3376,"NA":3378},{"trials":3358,"activeCount":98},[],{"trials":3360,"activeCount":98},[],{"trials":3362,"activeCount":98},[3363],{"nctId":3364,"briefTitle":3365,"status":214,"phases":3366,"primaryCompletion":3367,"completion":3368,"start":3369,"enrollment":983,"conditions":3370,"interventions":3372},"NCT04543682","A Clinical Trial Investigating Iloprost as Medication to Improve Bone Healing in Patients With Proximal Humeral Fracture",[87,88],"2024-05","2024-12","2022-05-12",[3371],"Proximal Humeral Fracture",[3355,3373],"0.25 ng\u002Fkg\u002Fmin Iloprost",{"trials":3375,"activeCount":98},[],{"trials":3377,"activeCount":98},[],{"trials":3379,"activeCount":98},[],{"intervention":3373,"totalTrials":94,"cells":3381},{"EARLY_PHASE1":3382,"PHASE1":3384,"PHASE2":3386,"PHASE3":3392,"PHASE4":3394,"NA":3396},{"trials":3383,"activeCount":98},[],{"trials":3385,"activeCount":98},[],{"trials":3387,"activeCount":98},[3388],{"nctId":3364,"briefTitle":3365,"status":214,"phases":3389,"primaryCompletion":3367,"completion":3368,"start":3369,"enrollment":983,"conditions":3390,"interventions":3391},[87,88],[3371],[3355,3373],{"trials":3393,"activeCount":98},[],{"trials":3395,"activeCount":98},[],{"trials":3397,"activeCount":98},[],{"intervention":3399,"totalTrials":94,"cells":3400},"rosiglitazone",{"EARLY_PHASE1":3401,"PHASE1":3403,"PHASE2":3405,"PHASE3":3416,"PHASE4":3418,"NA":3420},{"trials":3402,"activeCount":98},[],{"trials":3404,"activeCount":98},[],{"trials":3406,"activeCount":98},[3407],{"nctId":3408,"briefTitle":3409,"status":564,"phases":3410,"primaryCompletion":869,"completion":869,"start":3411,"enrollment":16,"conditions":3412,"interventions":3415},"NCT00370305","11ß-HSD1 and Metabolic Syndrome",[88],"2004-05",[3413,3414],"Metabolic Syndrome","Impaired Glucose Tolerance",[3399],{"trials":3417,"activeCount":98},[],{"trials":3419,"activeCount":98},[],{"trials":3421,"activeCount":98},[],{"intervention":3423,"totalTrials":94,"cells":3424},"Gemcitabine",{"EARLY_PHASE1":3425,"PHASE1":3427,"PHASE2":3429,"PHASE3":3440,"PHASE4":3442,"NA":3444},{"trials":3426,"activeCount":98},[],{"trials":3428,"activeCount":98},[],{"trials":3430,"activeCount":98},[3431],{"nctId":3432,"briefTitle":3433,"status":214,"phases":3434,"start":3435,"enrollment":2783,"conditions":3436,"interventions":3438},"NCT00168870","Study of Metastatic Ocular Melanoma",[88],"2003-02",[3437],"Ocular Melanoma",[3423,3439],"Treosulfan",{"trials":3441,"activeCount":98},[],{"trials":3443,"activeCount":98},[],{"trials":3445,"activeCount":98},[],{"intervention":3439,"totalTrials":94,"cells":3447},{"EARLY_PHASE1":3448,"PHASE1":3450,"PHASE2":3452,"PHASE3":3458,"PHASE4":3460,"NA":3462},{"trials":3449,"activeCount":98},[],{"trials":3451,"activeCount":98},[],{"trials":3453,"activeCount":98},[3454],{"nctId":3432,"briefTitle":3433,"status":214,"phases":3455,"start":3435,"enrollment":2783,"conditions":3456,"interventions":3457},[88],[3437],[3423,3439],{"trials":3459,"activeCount":98},[],{"trials":3461,"activeCount":98},[],{"trials":3463,"activeCount":98},[],{"intervention":3465,"totalTrials":94,"cells":3466},"Bendamustin\u002FRibomustin",{"EARLY_PHASE1":3467,"PHASE1":3469,"PHASE2":3471,"PHASE3":3481,"PHASE4":3483,"NA":3485},{"trials":3468,"activeCount":98},[],{"trials":3470,"activeCount":98},[],{"trials":3472,"activeCount":98},[3473],{"nctId":3474,"briefTitle":3475,"status":214,"phases":3476,"completion":1766,"start":3477,"enrollment":292,"conditions":3478,"interventions":3480},"NCT00168922","Study to Determine the Efficacy of Bendamustin in Patients With Recurrent Small Cell Lung Cancer (SCLC)",[88],"2001-02",[3479],"Recurrent Small Cell Lung Cancer",[3465],{"trials":3482,"activeCount":98},[],{"trials":3484,"activeCount":98},[],{"trials":3486,"activeCount":98},[],{"intervention":3488,"totalTrials":94,"cells":3489},"interferon-gamma",{"EARLY_PHASE1":3490,"PHASE1":3492,"PHASE2":3494,"PHASE3":3505,"PHASE4":3507,"NA":3509},{"trials":3491,"activeCount":98},[],{"trials":3493,"activeCount":98},[],{"trials":3495,"activeCount":98},[3496],{"nctId":3497,"briefTitle":3498,"status":214,"phases":3499,"start":2936,"enrollment":568,"conditions":3500,"interventions":3502},"NCT00244179","New Immunomodulatory Therapy Strategies in Chronic Reactive Arthritis",[88],[3501],"Reactive Arthritis",[3488,3503,3504],"infliximab","dmard",{"trials":3506,"activeCount":98},[],{"trials":3508,"activeCount":98},[],{"trials":3510,"activeCount":98},[],{"intervention":3503,"totalTrials":94,"cells":3512},{"EARLY_PHASE1":3513,"PHASE1":3515,"PHASE2":3517,"PHASE3":3523,"PHASE4":3525,"NA":3527},{"trials":3514,"activeCount":98},[],{"trials":3516,"activeCount":98},[],{"trials":3518,"activeCount":98},[3519],{"nctId":3497,"briefTitle":3498,"status":214,"phases":3520,"start":2936,"enrollment":568,"conditions":3521,"interventions":3522},[88],[3501],[3488,3503,3504],{"trials":3524,"activeCount":98},[],{"trials":3526,"activeCount":98},[],{"trials":3528,"activeCount":98},[],{"intervention":3504,"totalTrials":94,"cells":3530},{"EARLY_PHASE1":3531,"PHASE1":3533,"PHASE2":3535,"PHASE3":3541,"PHASE4":3543,"NA":3545},{"trials":3532,"activeCount":98},[],{"trials":3534,"activeCount":98},[],{"trials":3536,"activeCount":98},[3537],{"nctId":3497,"briefTitle":3498,"status":214,"phases":3538,"start":2936,"enrollment":568,"conditions":3539,"interventions":3540},[88],[3501],[3488,3503,3504],{"trials":3542,"activeCount":98},[],{"trials":3544,"activeCount":98},[],{"trials":3546,"activeCount":98},[],{"intervention":3548,"totalTrials":94,"cells":3549},"Fasenra Prefilled Syringe",{"EARLY_PHASE1":3550,"PHASE1":3552,"PHASE2":3554,"PHASE3":3565,"PHASE4":3567,"NA":3569},{"trials":3551,"activeCount":98},[],{"trials":3553,"activeCount":98},[],{"trials":3555,"activeCount":98},[3556],{"nctId":3557,"briefTitle":3558,"status":575,"phases":3559,"primaryCompletion":3560,"completion":3560,"start":3561,"enrollment":98,"conditions":3562,"interventions":3564},"NCT05528913","Benralizumab in Chronic Prurigo - Investigating Clinical Efficacy (BICPIC)",[88],"2023-10-19","2023-10",[3563],"Chronic Prurigo",[3548],{"trials":3566,"activeCount":98},[],{"trials":3568,"activeCount":98},[],{"trials":3570,"activeCount":98},[],{"intervention":3572,"totalTrials":94,"cells":3573},"Trichuris suis ova",{"EARLY_PHASE1":3574,"PHASE1":3576,"PHASE2":3578,"PHASE3":3588,"PHASE4":3590,"NA":3592},{"trials":3575,"activeCount":98},[],{"trials":3577,"activeCount":98},[],{"trials":3579,"activeCount":98},[3580],{"nctId":3581,"briefTitle":3582,"status":201,"phases":3583,"primaryCompletion":3584,"completion":2875,"start":3585,"enrollment":292,"conditions":3586,"interventions":3587},"NCT01413243","Trichuris Suis Ova (TSO)in Recurrent Remittent Multiple Sclerosis and Clinically Isolated Syndrome",[88],"2016-12","2012-09",[23],[3572],{"trials":3589,"activeCount":98},[],{"trials":3591,"activeCount":98},[],{"trials":3593,"activeCount":98},[],{"intervention":3595,"totalTrials":94,"cells":3596},"Bupropion",{"EARLY_PHASE1":3597,"PHASE1":3599,"PHASE2":3601,"PHASE3":3611,"PHASE4":3613,"NA":3615},{"trials":3598,"activeCount":98},[],{"trials":3600,"activeCount":98},[],{"trials":3602,"activeCount":98},[3603],{"nctId":3604,"briefTitle":3605,"status":564,"phases":3606,"primaryCompletion":2306,"completion":2306,"start":3320,"enrollment":568,"conditions":3607,"interventions":3610},"NCT01914965","Apathy Cure Through Bupropion in Huntington's Disease",[88],[3608,3609],"Apathy","Huntington's Disease",[3595],{"trials":3612,"activeCount":98},[],{"trials":3614,"activeCount":98},[],{"trials":3616,"activeCount":98},[],{"intervention":3618,"totalTrials":94,"cells":3619},"GM-CSF",{"EARLY_PHASE1":3620,"PHASE1":3622,"PHASE2":3624,"PHASE3":3635,"PHASE4":3637,"NA":3639},{"trials":3621,"activeCount":98},[],{"trials":3623,"activeCount":98},[],{"trials":3625,"activeCount":98},[3626],{"nctId":3627,"briefTitle":3628,"status":564,"phases":3629,"primaryCompletion":3630,"completion":3631,"start":611,"enrollment":1987,"conditions":3632,"interventions":3634},"NCT00252915","Reconstruction of Monocytic Immunocompetence by Granulocyte-macrophage-colony Stimulating Factor (GM-CSF) in Patients With Severe Sepsis and Septic Shock",[88],"2007-01","2007-04",[3633],"Sepsis",[3618],{"trials":3636,"activeCount":98},[],{"trials":3638,"activeCount":98},[],{"trials":3640,"activeCount":98},[],{"intervention":3642,"totalTrials":94,"cells":3643},"iloprost",{"EARLY_PHASE1":3644,"PHASE1":3646,"PHASE2":3648,"PHASE3":3662,"PHASE4":3664,"NA":3666},{"trials":3645,"activeCount":98},[],{"trials":3647,"activeCount":98},[],{"trials":3649,"activeCount":98},[3650],{"nctId":3651,"briefTitle":3652,"status":201,"phases":3653,"primaryCompletion":3654,"completion":3655,"start":3656,"enrollment":292,"conditions":3657,"interventions":3659},"NCT00622687","Effect of Different Iloprost Doses on Symptoms in Systemic Sclerosis",[88],"2003-12","2007-12","1997-09",[3658],"Systemic Sclerosis",[3642,3660,3661],"iloprost low dose","iloprost therapy up to 2 ng\u002Fkg x min",{"trials":3663,"activeCount":98},[],{"trials":3665,"activeCount":98},[],{"trials":3667,"activeCount":98},[],{"intervention":3660,"totalTrials":94,"cells":3669},{"EARLY_PHASE1":3670,"PHASE1":3672,"PHASE2":3674,"PHASE3":3680,"PHASE4":3682,"NA":3684},{"trials":3671,"activeCount":98},[],{"trials":3673,"activeCount":98},[],{"trials":3675,"activeCount":98},[3676],{"nctId":3651,"briefTitle":3652,"status":201,"phases":3677,"primaryCompletion":3654,"completion":3655,"start":3656,"enrollment":292,"conditions":3678,"interventions":3679},[88],[3658],[3642,3660,3661],{"trials":3681,"activeCount":98},[],{"trials":3683,"activeCount":98},[],{"trials":3685,"activeCount":98},[],{"intervention":3661,"totalTrials":94,"cells":3687},{"EARLY_PHASE1":3688,"PHASE1":3690,"PHASE2":3692,"PHASE3":3698,"PHASE4":3700,"NA":3702},{"trials":3689,"activeCount":98},[],{"trials":3691,"activeCount":98},[],{"trials":3693,"activeCount":98},[3694],{"nctId":3651,"briefTitle":3652,"status":201,"phases":3695,"primaryCompletion":3654,"completion":3655,"start":3656,"enrollment":292,"conditions":3696,"interventions":3697},[88],[3658],[3642,3660,3661],{"trials":3699,"activeCount":98},[],{"trials":3701,"activeCount":98},[],{"trials":3703,"activeCount":98},[],{"intervention":3705,"totalTrials":94,"cells":3706},"rituximab monotherapy",{"EARLY_PHASE1":3707,"PHASE1":3709,"PHASE2":3711,"PHASE3":3724,"PHASE4":3726,"NA":3728},{"trials":3708,"activeCount":98},[],{"trials":3710,"activeCount":98},[],{"trials":3712,"activeCount":98},[3713],{"nctId":3714,"briefTitle":3715,"status":564,"phases":3716,"primaryCompletion":2075,"completion":3717,"start":1766,"enrollment":3718,"conditions":3719,"interventions":3722},"NCT00590447","Risk Stratified Sequential Treatment for CD20-positive PTLD",[88],"2015-07",152,[3720,3721],"PTLD","Posttransplant Lymphoproliferative Disorder",[3705,3723],"sequential R-CHOP",{"trials":3725,"activeCount":98},[],{"trials":3727,"activeCount":98},[],{"trials":3729,"activeCount":98},[],{"intervention":3723,"totalTrials":94,"cells":3731},{"EARLY_PHASE1":3732,"PHASE1":3734,"PHASE2":3736,"PHASE3":3742,"PHASE4":3744,"NA":3746},{"trials":3733,"activeCount":98},[],{"trials":3735,"activeCount":98},[],{"trials":3737,"activeCount":98},[3738],{"nctId":3714,"briefTitle":3715,"status":564,"phases":3739,"primaryCompletion":2075,"completion":3717,"start":1766,"enrollment":3718,"conditions":3740,"interventions":3741},[88],[3720,3721],[3705,3723],{"trials":3743,"activeCount":98},[],{"trials":3745,"activeCount":98},[],{"trials":3747,"activeCount":98},[],{"intervention":3749,"totalTrials":94,"cells":3750},"Cyclosporine A",{"EARLY_PHASE1":3751,"PHASE1":3753,"PHASE2":3755,"PHASE3":3764,"PHASE4":3766,"NA":3768},{"trials":3752,"activeCount":98},[],{"trials":3754,"activeCount":98},[],{"trials":3756,"activeCount":98},[3757],{"nctId":3758,"briefTitle":3759,"status":564,"phases":3760,"primaryCompletion":269,"completion":269,"start":1926,"enrollment":983,"conditions":3761,"interventions":3763},"NCT01693393","Low Dose Cyclosporin A in Primary Sjögren Syndrome",[88],[3762],"Sjögren´s Syndrome",[3749],{"trials":3765,"activeCount":98},[],{"trials":3767,"activeCount":98},[],{"trials":3769,"activeCount":98},[],{"intervention":3771,"totalTrials":94,"cells":3772},"Cholecalciferol",{"EARLY_PHASE1":3773,"PHASE1":3775,"PHASE2":3777,"PHASE3":3787,"PHASE4":3789,"NA":3791},{"trials":3774,"activeCount":98},[],{"trials":3776,"activeCount":98},[],{"trials":3778,"activeCount":98},[3779],{"nctId":3780,"briefTitle":3781,"status":564,"phases":3782,"primaryCompletion":940,"completion":940,"start":204,"enrollment":3783,"conditions":3784,"interventions":3786},"NCT01466465","Vitamin D and Grass Pollen Specific Immunotherapy",[88],35,[3785],"Allergic Rhinoconjunctivitis",[3771],{"trials":3788,"activeCount":98},[],{"trials":3790,"activeCount":98},[],{"trials":3792,"activeCount":98},[],{"intervention":3794,"totalTrials":94,"cells":3795},"Cenicriviroc",{"EARLY_PHASE1":3796,"PHASE1":3798,"PHASE2":3800,"PHASE3":3811,"PHASE4":3813,"NA":3815},{"trials":3797,"activeCount":98},[],{"trials":3799,"activeCount":98},[],{"trials":3801,"activeCount":98},[3802],{"nctId":3803,"briefTitle":3804,"status":201,"phases":3805,"primaryCompletion":3806,"completion":3806,"start":3807,"enrollment":1445,"conditions":3808,"interventions":3810},"NCT04500418","Charité Trial of Cenicriviroc (CVC) Treatment for COVID-19 Patients",[88],"2021-07-27","2020-08-25",[3809],"Covid19",[3794],{"trials":3812,"activeCount":98},[],{"trials":3814,"activeCount":98},[],{"trials":3816,"activeCount":98},[],{"intervention":3818,"totalTrials":94,"cells":3819},"RM-493",{"EARLY_PHASE1":3820,"PHASE1":3822,"PHASE2":3824,"PHASE3":3834,"PHASE4":3836,"NA":3838},{"trials":3821,"activeCount":98},[],{"trials":3823,"activeCount":98},[],{"trials":3825,"activeCount":98},[3826],{"nctId":3827,"briefTitle":3828,"status":214,"phases":3829,"primaryCompletion":3830,"completion":939,"start":940,"enrollment":29,"conditions":3831,"interventions":3833},"NCT02507492","RM-493 Treatment Trial in Proopiomelanocortin (POMC) Deficient Patients",[88],"2018-01",[3832],"Homozygous or Compound Heterozygous POMC, LEPR or PCSK1 Gene Mutation",[3818],{"trials":3835,"activeCount":98},[],{"trials":3837,"activeCount":98},[],{"trials":3839,"activeCount":98},[],{"intervention":3841,"totalTrials":94,"cells":3842},"interferon beta treatment to add-on atorvastatin treatment",{"EARLY_PHASE1":3843,"PHASE1":3845,"PHASE2":3847,"PHASE3":3859,"PHASE4":3861,"NA":3863},{"trials":3844,"activeCount":98},[],{"trials":3846,"activeCount":98},[],{"trials":3848,"activeCount":98},[3849],{"nctId":3850,"briefTitle":3851,"status":564,"phases":3852,"primaryCompletion":589,"start":3853,"enrollment":3854,"conditions":3855,"interventions":3857},"NCT00616187","Atorvastatin in Relapsing-Remitting Multiple Sclerosis",[88],"2003-10",41,[3856],"Relapsing Remitting Multiple Sclerosis",[3841,3858],"untreated to atorvastatin treatment",{"trials":3860,"activeCount":98},[],{"trials":3862,"activeCount":98},[],{"trials":3864,"activeCount":98},[],{"intervention":3858,"totalTrials":94,"cells":3866},{"EARLY_PHASE1":3867,"PHASE1":3869,"PHASE2":3871,"PHASE3":3877,"PHASE4":3879,"NA":3881},{"trials":3868,"activeCount":98},[],{"trials":3870,"activeCount":98},[],{"trials":3872,"activeCount":98},[3873],{"nctId":3850,"briefTitle":3851,"status":564,"phases":3874,"primaryCompletion":589,"start":3853,"enrollment":3854,"conditions":3875,"interventions":3876},[88],[3856],[3841,3858],{"trials":3878,"activeCount":98},[],{"trials":3880,"activeCount":98},[],{"trials":3882,"activeCount":98},[],{"intervention":3884,"totalTrials":94,"cells":3885},"Pazopanib",{"EARLY_PHASE1":3886,"PHASE1":3888,"PHASE2":3890,"PHASE3":3901,"PHASE4":3903,"NA":3905},{"trials":3887,"activeCount":98},[],{"trials":3889,"activeCount":98},[],{"trials":3891,"activeCount":98},[3892],{"nctId":3893,"briefTitle":3894,"status":564,"phases":3895,"primaryCompletion":3896,"completion":3896,"start":801,"enrollment":2284,"conditions":3897,"interventions":3899},"NCT01503372","FLO +\u002F- Pazopanib as First-line Treatment in Advanced Gastric Cancer",[88],"2017-12-14",[3898],"Advanced Gastric Cancer",[3884,3900],"5-FU, Oxaliplatin, Leukovorin",{"trials":3902,"activeCount":98},[],{"trials":3904,"activeCount":98},[],{"trials":3906,"activeCount":98},[],{"intervention":3900,"totalTrials":94,"cells":3908},{"EARLY_PHASE1":3909,"PHASE1":3911,"PHASE2":3913,"PHASE3":3919,"PHASE4":3921,"NA":3923},{"trials":3910,"activeCount":98},[],{"trials":3912,"activeCount":98},[],{"trials":3914,"activeCount":98},[3915],{"nctId":3893,"briefTitle":3894,"status":564,"phases":3916,"primaryCompletion":3896,"completion":3896,"start":801,"enrollment":2284,"conditions":3917,"interventions":3918},[88],[3898],[3884,3900],{"trials":3920,"activeCount":98},[],{"trials":3922,"activeCount":98},[],{"trials":3924,"activeCount":98},[],{"intervention":3926,"totalTrials":94,"cells":3927},"Flupirtine",{"EARLY_PHASE1":3928,"PHASE1":3930,"PHASE2":3932,"PHASE3":3940,"PHASE4":3942,"NA":3944},{"trials":3929,"activeCount":98},[],{"trials":3931,"activeCount":98},[],{"trials":3933,"activeCount":98},[3934],{"nctId":3935,"briefTitle":3936,"status":201,"phases":3937,"primaryCompletion":1723,"completion":1723,"start":3655,"enrollment":983,"conditions":3938,"interventions":3939},"NCT00623415","Flupirtine as Oral Treatment in Multiple Sclerosis",[88],[3856],[3926],{"trials":3941,"activeCount":98},[],{"trials":3943,"activeCount":98},[],{"trials":3945,"activeCount":98},[],{"intervention":3947,"totalTrials":94,"cells":3948},"intraarticular morphine",{"EARLY_PHASE1":3949,"PHASE1":3951,"PHASE2":3953,"PHASE3":3964,"PHASE4":3966,"NA":3968},{"trials":3950,"activeCount":98},[],{"trials":3952,"activeCount":98},[],{"trials":3954,"activeCount":98},[3955],{"nctId":3956,"briefTitle":3957,"status":214,"phases":3958,"completion":1008,"start":3959,"enrollment":1724,"conditions":3960,"interventions":3962},"NCT00244153","Intraarticular Opioids Vs Glucocorticosteroids in Gonarthritis",[87,88],"2004-06",[3961],"Rheumatic Disease",[3947,3963],"intraarticular dexamethasone",{"trials":3965,"activeCount":98},[],{"trials":3967,"activeCount":98},[],{"trials":3969,"activeCount":98},[],{"intervention":3963,"totalTrials":94,"cells":3971},{"EARLY_PHASE1":3972,"PHASE1":3974,"PHASE2":3976,"PHASE3":3982,"PHASE4":3984,"NA":3986},{"trials":3973,"activeCount":98},[],{"trials":3975,"activeCount":98},[],{"trials":3977,"activeCount":98},[3978],{"nctId":3956,"briefTitle":3957,"status":214,"phases":3979,"completion":1008,"start":3959,"enrollment":1724,"conditions":3980,"interventions":3981},[87,88],[3961],[3947,3963],{"trials":3983,"activeCount":98},[],{"trials":3985,"activeCount":98},[],{"trials":3987,"activeCount":98},[],{"intervention":3989,"totalTrials":94,"cells":3990},"Daratumumab",{"EARLY_PHASE1":3991,"PHASE1":3993,"PHASE2":3995,"PHASE3":4005,"PHASE4":4007,"NA":4009},{"trials":3992,"activeCount":98},[],{"trials":3994,"activeCount":98},[],{"trials":3996,"activeCount":98},[3997],{"nctId":3998,"briefTitle":3999,"status":214,"phases":4000,"primaryCompletion":4001,"completion":38,"start":4002,"enrollment":29,"conditions":4003,"interventions":4004},"NCT04810754","An Open Label Study to Evaluate Daratumumab in Participants With Moderate to Severe Systemic Lupus Erythematosus",[88],"2023-03-31","2021-06-30",[272],[3989],{"trials":4006,"activeCount":98},[],{"trials":4008,"activeCount":98},[],{"trials":4010,"activeCount":98},[],{"intervention":4012,"totalTrials":94,"cells":4013},"Docetaxel",{"EARLY_PHASE1":4014,"PHASE1":4016,"PHASE2":4018,"PHASE3":4027,"PHASE4":4029,"NA":4031},{"trials":4015,"activeCount":98},[],{"trials":4017,"activeCount":98},[],{"trials":4019,"activeCount":98},[4020],{"nctId":4021,"briefTitle":4022,"status":564,"phases":4023,"completion":3655,"start":590,"enrollment":473,"conditions":4024,"interventions":4025},"NCT00142038","Docetaxel and Capecitabine in Advanced Gastric Cancer",[88],[2213,2214],[4012,4026],"Capecitabine",{"trials":4028,"activeCount":98},[],{"trials":4030,"activeCount":98},[],{"trials":4032,"activeCount":98},[],{"intervention":4026,"totalTrials":94,"cells":4034},{"EARLY_PHASE1":4035,"PHASE1":4037,"PHASE2":4039,"PHASE3":4045,"PHASE4":4047,"NA":4049},{"trials":4036,"activeCount":98},[],{"trials":4038,"activeCount":98},[],{"trials":4040,"activeCount":98},[4041],{"nctId":4021,"briefTitle":4022,"status":564,"phases":4042,"completion":3655,"start":590,"enrollment":473,"conditions":4043,"interventions":4044},[88],[2213,2214],[4012,4026],{"trials":4046,"activeCount":98},[],{"trials":4048,"activeCount":98},[],{"trials":4050,"activeCount":98},[],{"intervention":4052,"totalTrials":94,"cells":4053},"Rupatadine",{"EARLY_PHASE1":4054,"PHASE1":4056,"PHASE2":4058,"PHASE3":4067,"PHASE4":4069,"NA":4071},{"trials":4055,"activeCount":98},[],{"trials":4057,"activeCount":98},[],{"trials":4059,"activeCount":98},[4060],{"nctId":4061,"briefTitle":4062,"status":564,"phases":4063,"primaryCompletion":4064,"completion":269,"start":3320,"enrollment":16,"conditions":4065,"interventions":4066},"NCT01605487","Study to Assess Efficacy, Safety and Mechanism of Rupatadine in Cold Urticaria",[88],"2013-09",[1869],[4052,4052,4052,4052,4052,4052],{"trials":4068,"activeCount":98},[],{"trials":4070,"activeCount":98},[],{"trials":4072,"activeCount":98},[],{"intervention":4074,"totalTrials":94,"cells":4075},"Combined systemic and intrathecal chemotherapy followed by HD-ASCT",{"EARLY_PHASE1":4076,"PHASE1":4078,"PHASE2":4080,"PHASE3":4090,"PHASE4":4092,"NA":4094},{"trials":4077,"activeCount":98},[],{"trials":4079,"activeCount":98},[],{"trials":4081,"activeCount":98},[4082],{"nctId":4083,"briefTitle":4084,"status":214,"phases":4085,"primaryCompletion":204,"completion":4086,"start":218,"enrollment":983,"conditions":4087,"interventions":4089},"NCT01148173","High-dose Chemotherapy and Stem Cell Transplantation for Central Nervous System (CNS) Relapse of Aggressive Lymphomas",[88],"2012-10",[4088],"Lymphoma, Non-Hodgkin",[4074],{"trials":4091,"activeCount":98},[],{"trials":4093,"activeCount":98},[],{"trials":4095,"activeCount":98},[],{"intervention":4097,"totalTrials":94,"cells":4098},"Simvastatin 40mg",{"EARLY_PHASE1":4099,"PHASE1":4101,"PHASE2":4103,"PHASE3":4114,"PHASE4":4116,"NA":4118},{"trials":4100,"activeCount":98},[],{"trials":4102,"activeCount":98},[],{"trials":4104,"activeCount":98},[4105],{"nctId":4106,"briefTitle":4107,"status":564,"phases":4108,"primaryCompletion":4109,"completion":4109,"start":4110,"enrollment":4111,"conditions":4112,"interventions":4113},"NCT04301271","Simvastatin add-on Treatment to Standard Antidepressant Therapy in Patients With Comorbid Obesity and Major Depression",[88],"2024-06-06","2020-08-13",161,[497,1990],[4097],{"trials":4115,"activeCount":98},[],{"trials":4117,"activeCount":98},[],{"trials":4119,"activeCount":98},[],{"intervention":4121,"totalTrials":94,"cells":4122},"TPF induction chemotherapy",{"EARLY_PHASE1":4123,"PHASE1":4125,"PHASE2":4127,"PHASE3":4140,"PHASE4":4142,"NA":4144},{"trials":4124,"activeCount":98},[],{"trials":4126,"activeCount":98},[],{"trials":4128,"activeCount":98},[4129],{"nctId":4130,"briefTitle":4131,"status":564,"phases":4132,"primaryCompletion":4133,"completion":3344,"start":2137,"enrollment":4134,"conditions":4135,"interventions":4138},"NCT01181401","InductionChemo-Radio-Antibody-Treatment",[88],"2015-04",94,[4136,4137],"Squamous Cell Carcinoma of the Head","Squamous Cell Carcinoma of the Neck",[4121,4139],"TPF experimental",{"trials":4141,"activeCount":98},[],{"trials":4143,"activeCount":98},[],{"trials":4145,"activeCount":98},[],{"intervention":4139,"totalTrials":94,"cells":4147},{"EARLY_PHASE1":4148,"PHASE1":4150,"PHASE2":4152,"PHASE3":4158,"PHASE4":4160,"NA":4162},{"trials":4149,"activeCount":98},[],{"trials":4151,"activeCount":98},[],{"trials":4153,"activeCount":98},[4154],{"nctId":4130,"briefTitle":4131,"status":564,"phases":4155,"primaryCompletion":4133,"completion":3344,"start":2137,"enrollment":4134,"conditions":4156,"interventions":4157},[88],[4136,4137],[4121,4139],{"trials":4159,"activeCount":98},[],{"trials":4161,"activeCount":98},[],{"trials":4163,"activeCount":98},[],{"intervention":4165,"totalTrials":94,"cells":4166},"Methylprednisolone",{"EARLY_PHASE1":4167,"PHASE1":4169,"PHASE2":4171,"PHASE3":4183,"PHASE4":4185,"NA":4187},{"trials":4168,"activeCount":98},[],{"trials":4170,"activeCount":98},[],{"trials":4172,"activeCount":98},[4173],{"nctId":4174,"briefTitle":4175,"status":201,"phases":4176,"primaryCompletion":4177,"completion":4178,"start":4179,"enrollment":2422,"conditions":4180,"interventions":4182},"NCT05986422","Methylprednisolone in Patients With Cognitive Deficits in Post-COVID-19 Syndrome (PCS)",[88],"2025-03-14","2026-02-19","2023-10-01",[4181],"Post-COVID-19 Syndrome",[4165],{"trials":4184,"activeCount":98},[],{"trials":4186,"activeCount":98},[],{"trials":4188,"activeCount":98},[],{"intervention":4190,"totalTrials":94,"cells":4191},"Sildenafil therapy",{"EARLY_PHASE1":4192,"PHASE1":4194,"PHASE2":4196,"PHASE3":4207,"PHASE4":4209,"NA":4211},{"trials":4193,"activeCount":98},[],{"trials":4195,"activeCount":98},[],{"trials":4197,"activeCount":98},[4198],{"nctId":4199,"briefTitle":4200,"status":564,"phases":4201,"primaryCompletion":895,"completion":4202,"start":1704,"enrollment":4203,"conditions":4204,"interventions":4206},"NCT00624273","Sildenafil for Treatment of Digital Ulcers in Patients With Systemic Sclerosis",[88],"2007-02",17,[4205],"Active Digital Ulcers",[4190],{"trials":4208,"activeCount":98},[],{"trials":4210,"activeCount":98},[],{"trials":4212,"activeCount":98},[],{"intervention":4214,"totalTrials":94,"cells":4215},"Erenumab",{"EARLY_PHASE1":4216,"PHASE1":4218,"PHASE2":4220,"PHASE3":4235,"PHASE4":4237,"NA":4239},{"trials":4217,"activeCount":98},[],{"trials":4219,"activeCount":98},[],{"trials":4221,"activeCount":98},[4222],{"nctId":4223,"briefTitle":4224,"status":564,"phases":4225,"primaryCompletion":4226,"completion":4226,"start":4227,"enrollment":4228,"conditions":4229,"interventions":4234},"NCT04970355","Efficacy of Erenumab in Chronic Cluster Headache",[88],"2023-09-27","2021-12-02",101,[4230,4231,4232,4233],"Cluster Headache","Trigeminal Autonomic Cephalalgias","Headache Disorders, Primary","Brain Disease",[4214],{"trials":4236,"activeCount":98},[],{"trials":4238,"activeCount":98},[],{"trials":4240,"activeCount":98},[],{"intervention":4242,"totalTrials":94,"cells":4243},"Doxazosin",{"EARLY_PHASE1":4244,"PHASE1":4246,"PHASE2":4248,"PHASE3":4262,"PHASE4":4264,"NA":4266},{"trials":4245,"activeCount":98},[],{"trials":4247,"activeCount":98},[],{"trials":4249,"activeCount":98},[4250],{"nctId":4251,"briefTitle":4252,"status":4253,"phases":4254,"primaryCompletion":4255,"completion":4256,"start":4257,"enrollment":4258,"conditions":4259,"interventions":4260},"NCT05360953","Treating Nightmares in Posttraumatic Stress Disorder With Clonidine and Doxazosin","SUSPENDED",[88],"2025-08-08","2026-07-31","2022-06-17",53,[3281],[4261,4242],"Clonidine",{"trials":4263,"activeCount":98},[],{"trials":4265,"activeCount":98},[],{"trials":4267,"activeCount":98},[],{"intervention":4269,"totalTrials":94,"cells":4270},"Contraloid acetate",{"EARLY_PHASE1":4271,"PHASE1":4273,"PHASE2":4284,"PHASE3":4286,"PHASE4":4288,"NA":4290},{"trials":4272,"activeCount":98},[],{"trials":4274,"activeCount":98},[4275],{"nctId":4276,"briefTitle":4277,"status":564,"phases":4278,"primaryCompletion":4279,"completion":4279,"start":4280,"enrollment":2189,"conditions":4281,"interventions":4283},"NCT04711486","Evaluation of Safety of Contraloid Acetate in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease",[87],"2022-01-13","2020-12-08",[4282],"Mild Cognitive Impairment Due to Alzheimer's Disease",[4269],{"trials":4285,"activeCount":98},[],{"trials":4287,"activeCount":98},[],{"trials":4289,"activeCount":98},[],{"trials":4291,"activeCount":98},[],{"intervention":4293,"totalTrials":94,"cells":4294},"ZK200775",{"EARLY_PHASE1":4295,"PHASE1":4297,"PHASE2":4309,"PHASE3":4311,"PHASE4":4313,"NA":4315},{"trials":4296,"activeCount":98},[],{"trials":4298,"activeCount":98},[4299],{"nctId":4300,"briefTitle":4301,"status":564,"phases":4302,"primaryCompletion":4303,"completion":4303,"start":4304,"enrollment":11,"conditions":4305,"interventions":4307},"NCT00999284","Ophthalmologic Examinations After Infusion of ZK200775",[87],"1998-04","1996-12",[4306],"Visual Acuity",[4293,4293,4308],"Sodium Chloride",{"trials":4310,"activeCount":98},[],{"trials":4312,"activeCount":98},[],{"trials":4314,"activeCount":98},[],{"trials":4316,"activeCount":98},[],{"intervention":4308,"totalTrials":94,"cells":4318},{"EARLY_PHASE1":4319,"PHASE1":4321,"PHASE2":4327,"PHASE3":4329,"PHASE4":4331,"NA":4333},{"trials":4320,"activeCount":98},[],{"trials":4322,"activeCount":98},[4323],{"nctId":4300,"briefTitle":4301,"status":564,"phases":4324,"primaryCompletion":4303,"completion":4303,"start":4304,"enrollment":11,"conditions":4325,"interventions":4326},[87],[4306],[4293,4293,4308],{"trials":4328,"activeCount":98},[],{"trials":4330,"activeCount":98},[],{"trials":4332,"activeCount":98},[],{"trials":4334,"activeCount":98},[],{"intervention":4336,"totalTrials":94,"cells":4337},"Citalopram",{"EARLY_PHASE1":4338,"PHASE1":4340,"PHASE2":4349,"PHASE3":4351,"PHASE4":4353,"NA":4355},{"trials":4339,"activeCount":98},[],{"trials":4341,"activeCount":98},[4342],{"nctId":4343,"briefTitle":4344,"status":564,"phases":4345,"primaryCompletion":2075,"completion":2075,"start":2707,"enrollment":568,"conditions":4346,"interventions":4348},"NCT02092974","Mechanism of tDCS-induced Learning Enhancement - the Role of Serotonin",[87],[4347],"Healthy Young and Older Adults",[4336],{"trials":4350,"activeCount":98},[],{"trials":4352,"activeCount":98},[],{"trials":4354,"activeCount":98},[],{"trials":4356,"activeCount":98},[],{"intervention":4358,"totalTrials":94,"cells":4359},"Homeopathic drug C12",{"EARLY_PHASE1":4360,"PHASE1":4362,"PHASE2":4370,"PHASE3":4372,"PHASE4":4374,"NA":4376},{"trials":4361,"activeCount":98},[],{"trials":4363,"activeCount":98},[4364],{"nctId":4365,"briefTitle":4366,"status":564,"phases":4367,"primaryCompletion":2587,"completion":2137,"start":1926,"enrollment":649,"conditions":4368,"interventions":4369},"NCT01061229","Homeopathic Drug Proving Trial",[87],[1989],[4358],{"trials":4371,"activeCount":98},[],{"trials":4373,"activeCount":98},[],{"trials":4375,"activeCount":98},[],{"trials":4377,"activeCount":98},[],{"intervention":4379,"totalTrials":94,"cells":4380},"TCAs, SSRIs, NARIs, SNRIs, Lithium",{"EARLY_PHASE1":4381,"PHASE1":4383,"PHASE2":4392,"PHASE3":4394,"PHASE4":4396,"NA":4398},{"trials":4382,"activeCount":98},[],{"trials":4384,"activeCount":98},[4385],{"nctId":4386,"briefTitle":4387,"status":564,"phases":4388,"primaryCompletion":1926,"completion":567,"start":2259,"enrollment":4389,"conditions":4390,"interventions":4391},"NCT00437385","Evaluation of Three Continuation Therapies After ECT Concerning Efficacy and Cognition in Severly Depressed Patients",[87],90,[31,2139],[4379],{"trials":4393,"activeCount":98},[],{"trials":4395,"activeCount":98},[],{"trials":4397,"activeCount":98},[],{"trials":4399,"activeCount":98},[],{"intervention":4401,"totalTrials":551,"cells":4402},"Hydrocortisone",{"EARLY_PHASE1":4403,"PHASE1":4405,"PHASE2":4407,"PHASE3":4409,"PHASE4":4420,"NA":4422},{"trials":4404,"activeCount":98},[],{"trials":4406,"activeCount":98},[],{"trials":4408,"activeCount":98},[],{"trials":4410,"activeCount":98},[4411],{"nctId":4412,"briefTitle":4413,"status":564,"phases":4414,"primaryCompletion":4415,"completion":4415,"start":2188,"enrollment":4416,"conditions":4417,"interventions":4419},"NCT00670254","Hydrocortisone for Prevention of Septic Shock",[89],"2013-08",380,[4418],"Severe Sepsis",[4401],{"trials":4421,"activeCount":98},[],{"trials":4423,"activeCount":98},[4424,4432],{"nctId":4425,"briefTitle":4426,"status":564,"phases":4427,"primaryCompletion":4428,"completion":4429,"start":1168,"enrollment":219,"conditions":4430,"interventions":4431},"NCT02552654","Cortisol and the Formation of Intrusive Memories",[91],"2015-11","2016-01",[523],[4401],{"nctId":4433,"briefTitle":4434,"status":564,"phases":4435,"primaryCompletion":4436,"completion":4436,"start":4437,"enrollment":4438,"conditions":4439,"interventions":4441},"NCT02523664","Neural Correlates of Stress Hormones",[91],"2018-12","2014-01",78,[4440,522],"Borderline Personality Disorder",[4401],{"intervention":2034,"totalTrials":249,"cells":4443},{"EARLY_PHASE1":4444,"PHASE1":4446,"PHASE2":4448,"PHASE3":4450,"PHASE4":4456,"NA":4458},{"trials":4445,"activeCount":98},[],{"trials":4447,"activeCount":98},[],{"trials":4449,"activeCount":98},[],{"trials":4451,"activeCount":98},[4452],{"nctId":2028,"briefTitle":2029,"status":564,"phases":4453,"primaryCompletion":1537,"completion":1537,"start":1059,"enrollment":2031,"conditions":4454,"interventions":4455},[89],[31],[2034,2017,2035],{"trials":4457,"activeCount":98},[],{"trials":4459,"activeCount":98},[4460],{"nctId":4461,"briefTitle":4462,"status":564,"phases":4463,"primaryCompletion":1009,"completion":1009,"start":3140,"enrollment":4464,"conditions":4465,"interventions":4466},"NCT00232700","Investigation of a Combination Treatment of Escitalopram and rTMS",[91],42,[2832],[2034],{"intervention":4468,"totalTrials":249,"cells":4469},"Fludrocortisone",{"EARLY_PHASE1":4470,"PHASE1":4472,"PHASE2":4474,"PHASE3":4476,"PHASE4":4478,"NA":4480},{"trials":4471,"activeCount":98},[],{"trials":4473,"activeCount":98},[],{"trials":4475,"activeCount":98},[],{"trials":4477,"activeCount":98},[],{"trials":4479,"activeCount":98},[],{"trials":4481,"activeCount":98},[4482,4491],{"nctId":4483,"briefTitle":4484,"status":564,"phases":4485,"primaryCompletion":4486,"completion":4486,"start":4487,"enrollment":896,"conditions":4488,"interventions":4489},"NCT03062150","Mineralocorticoid Receptor, NMDA Receptor and Cognitive Function in Depression",[91],"2019-02-11","2016-09-27",[2139],[4468,4490],"D-Cycloserine",{"nctId":4492,"briefTitle":4493,"status":564,"phases":4494,"primaryCompletion":290,"completion":290,"start":4495,"enrollment":4496,"conditions":4497,"interventions":4498},"NCT05310253","Stress & Social Cognition in BPD (part 2)",[91],"2022-02-01",240,[4440],[4468],{"intervention":4490,"totalTrials":249,"cells":4500},{"EARLY_PHASE1":4501,"PHASE1":4503,"PHASE2":4505,"PHASE3":4515,"PHASE4":4517,"NA":4519},{"trials":4502,"activeCount":98},[],{"trials":4504,"activeCount":98},[],{"trials":4506,"activeCount":98},[4507],{"nctId":4508,"briefTitle":4509,"status":564,"phases":4510,"primaryCompletion":2306,"completion":2306,"start":801,"enrollment":4511,"conditions":4512,"interventions":4514},"NCT01928823","Augmentation of Psychotherapy With D-Cycloserine in Agoraphobia",[88],73,[4513],"Agoraphobia",[4490],{"trials":4516,"activeCount":98},[],{"trials":4518,"activeCount":98},[],{"trials":4520,"activeCount":98},[4521],{"nctId":4483,"briefTitle":4484,"status":564,"phases":4522,"primaryCompletion":4486,"completion":4486,"start":4487,"enrollment":896,"conditions":4523,"interventions":4524},[91],[2139],[4468,4490],{"intervention":4526,"totalTrials":249,"cells":4527},"yohimbine",{"EARLY_PHASE1":4528,"PHASE1":4530,"PHASE2":4532,"PHASE3":4534,"PHASE4":4536,"NA":4538},{"trials":4529,"activeCount":98},[],{"trials":4531,"activeCount":98},[],{"trials":4533,"activeCount":98},[],{"trials":4535,"activeCount":98},[],{"trials":4537,"activeCount":98},[],{"trials":4539,"activeCount":98},[4540,4550],{"nctId":4541,"briefTitle":4542,"status":564,"phases":4543,"primaryCompletion":4544,"completion":4545,"start":2716,"enrollment":4546,"conditions":4547,"interventions":4549},"NCT02470026","Noradrenergic Activity, Cognition and Major Depressive Disorder",[91],"2017-11","2018-10",131,[2832,4548],"Early Life Trauma",[4526],{"nctId":4551,"briefTitle":4552,"status":564,"phases":4553,"primaryCompletion":269,"completion":269,"start":4554,"enrollment":4555,"conditions":4556,"interventions":4557},"NCT02541071","Influence of the Noradrenergic System on the Formation of Intrusive Memories",[91],"2013-11",118,[523],[4558,4261],"Yohimbine",{"intervention":4261,"totalTrials":249,"cells":4560},{"EARLY_PHASE1":4561,"PHASE1":4563,"PHASE2":4565,"PHASE3":4571,"PHASE4":4573,"NA":4575},{"trials":4562,"activeCount":98},[],{"trials":4564,"activeCount":98},[],{"trials":4566,"activeCount":98},[4567],{"nctId":4251,"briefTitle":4252,"status":4253,"phases":4568,"primaryCompletion":4255,"completion":4256,"start":4257,"enrollment":4258,"conditions":4569,"interventions":4570},[88],[3281],[4261,4242],{"trials":4572,"activeCount":98},[],{"trials":4574,"activeCount":98},[],{"trials":4576,"activeCount":98},[4577],{"nctId":4551,"briefTitle":4552,"status":564,"phases":4578,"primaryCompletion":269,"completion":269,"start":4554,"enrollment":4555,"conditions":4579,"interventions":4580},[91],[523],[4558,4261],{"intervention":4582,"totalTrials":94,"cells":4583},"Antidepressant",{"EARLY_PHASE1":4584,"PHASE1":4586,"PHASE2":4588,"PHASE3":4590,"PHASE4":4592,"NA":4594},{"trials":4585,"activeCount":98},[],{"trials":4587,"activeCount":98},[],{"trials":4589,"activeCount":98},[],{"trials":4591,"activeCount":98},[],{"trials":4593,"activeCount":98},[],{"trials":4595,"activeCount":98},[4596],{"nctId":4597,"briefTitle":4598,"status":564,"phases":4599,"primaryCompletion":4600,"completion":4601,"start":259,"enrollment":4602,"conditions":4603,"interventions":4604},"NCT02871141","Multimodal Imaging of ECT Effects",[],"2021-05-31","2021-12-31",68,[2832],[4582],{"intervention":4606,"totalTrials":94,"cells":4607},"Etomidate vs Propofol as induction agent",{"EARLY_PHASE1":4608,"PHASE1":4610,"PHASE2":4612,"PHASE3":4614,"PHASE4":4616,"NA":4618},{"trials":4609,"activeCount":98},[],{"trials":4611,"activeCount":98},[],{"trials":4613,"activeCount":98},[],{"trials":4615,"activeCount":98},[],{"trials":4617,"activeCount":98},[],{"trials":4619,"activeCount":98},[4620],{"nctId":4621,"briefTitle":4622,"status":564,"phases":4623,"primaryCompletion":4624,"completion":4624,"start":4625,"enrollment":4626,"conditions":4627,"interventions":4629},"NCT04281706","Impact of Etomidate vs. Propofol on Infectious Complications Post Cardiac Surgery",[],"2021-01-01","2019-10-15",1495,[4628],"Postoperative Complications",[4606],{"intervention":4631,"totalTrials":94,"cells":4632},"Dronabinol 2.5 mg",{"EARLY_PHASE1":4633,"PHASE1":4635,"PHASE2":4637,"PHASE3":4639,"PHASE4":4641,"NA":4643},{"trials":4634,"activeCount":98},[],{"trials":4636,"activeCount":98},[],{"trials":4638,"activeCount":98},[],{"trials":4640,"activeCount":98},[],{"trials":4642,"activeCount":98},[],{"trials":4644,"activeCount":98},[4645],{"nctId":4646,"briefTitle":4647,"status":564,"phases":4648,"primaryCompletion":4649,"completion":4649,"start":4650,"enrollment":2076,"conditions":4651,"interventions":4653},"NCT05226351","Activation of the Endocannabinoid System and Cognition",[91],"2024-08-15","2022-03-01",[4652],"Post Traumatic Stress Disorder",[4631],{"intervention":4655,"totalTrials":94,"cells":4656},"Hyperbaric oxygen therapy",{"EARLY_PHASE1":4657,"PHASE1":4659,"PHASE2":4661,"PHASE3":4663,"PHASE4":4665,"NA":4667},{"trials":4658,"activeCount":98},[],{"trials":4660,"activeCount":98},[],{"trials":4662,"activeCount":98},[],{"trials":4664,"activeCount":98},[],{"trials":4666,"activeCount":98},[],{"trials":4668,"activeCount":98},[4669],{"nctId":4670,"briefTitle":4671,"status":564,"phases":4672,"primaryCompletion":4673,"completion":4673,"start":4674,"enrollment":219,"conditions":4675,"interventions":4676},"NCT06118138","Hyperbaric High Pressure Oxygen Therapy in Post-COVID Syndrome and ME\u002FCFS",[],"2025-12-31","2023-07-15",[356],[4655],{"intervention":4678,"totalTrials":94,"cells":4679},"Clonidin",{"EARLY_PHASE1":4680,"PHASE1":4682,"PHASE2":4684,"PHASE3":4686,"PHASE4":4688,"NA":4690},{"trials":4681,"activeCount":98},[],{"trials":4683,"activeCount":98},[],{"trials":4685,"activeCount":98},[],{"trials":4687,"activeCount":98},[],{"trials":4689,"activeCount":98},[],{"trials":4691,"activeCount":98},[4692],{"nctId":4693,"briefTitle":4694,"status":564,"phases":4695,"primaryCompletion":4001,"completion":4001,"start":4650,"enrollment":2937,"conditions":4696,"interventions":4697},"NCT05318248","The Role of Stress Neuromodulators in Decision Making Under Risk (Part II)",[91],[410],[4678],{"intervention":4699,"totalTrials":94,"cells":4700},"SPRANC Block group",{"EARLY_PHASE1":4701,"PHASE1":4703,"PHASE2":4705,"PHASE3":4707,"PHASE4":4709,"NA":4711},{"trials":4702,"activeCount":98},[],{"trials":4704,"activeCount":98},[],{"trials":4706,"activeCount":98},[],{"trials":4708,"activeCount":98},[],{"trials":4710,"activeCount":98},[],{"trials":4712,"activeCount":98},[4713],{"nctId":4714,"briefTitle":4715,"status":4253,"phases":4716,"primaryCompletion":4717,"completion":4717,"start":4718,"enrollment":568,"conditions":4719,"interventions":4721},"NCT03081897","Regional Anaesthesia and Substance P in Head and Neck Cancer",[91],"2023-07-01","2016-07",[4720],"Head and Neck Cancer",[4699,4722],"SPRANC Control group",{"intervention":4722,"totalTrials":94,"cells":4724},{"EARLY_PHASE1":4725,"PHASE1":4727,"PHASE2":4729,"PHASE3":4731,"PHASE4":4733,"NA":4735},{"trials":4726,"activeCount":98},[],{"trials":4728,"activeCount":98},[],{"trials":4730,"activeCount":98},[],{"trials":4732,"activeCount":98},[],{"trials":4734,"activeCount":98},[],{"trials":4736,"activeCount":98},[4737],{"nctId":4714,"briefTitle":4715,"status":4253,"phases":4738,"primaryCompletion":4717,"completion":4717,"start":4718,"enrollment":568,"conditions":4739,"interventions":4740},[91],[4720],[4699,4722],{"intervention":4742,"totalTrials":94,"cells":4743},"Sunitinib",{"EARLY_PHASE1":4744,"PHASE1":4746,"PHASE2":4748,"PHASE3":4750,"PHASE4":4752,"NA":4754},{"trials":4745,"activeCount":98},[],{"trials":4747,"activeCount":98},[],{"trials":4749,"activeCount":98},[],{"trials":4751,"activeCount":98},[],{"trials":4753,"activeCount":98},[],{"trials":4755,"activeCount":98},[4756],{"nctId":4757,"briefTitle":4758,"status":564,"phases":4759,"primaryCompletion":4760,"completion":472,"start":4761,"enrollment":1513,"conditions":4762,"interventions":4765},"NCT04368546","Sunitinib Treatment on Tissue Sodium Accumulation (TSS2)",[],"2019-02-01","2015-11-01",[4763,1222,4764],"Renal Cell Cancer Metastatic","Sodium Imbalance",[4742],{"intervention":4767,"totalTrials":94,"cells":4768},"MRI using a hepatobiliary phase contrast agent",{"EARLY_PHASE1":4769,"PHASE1":4771,"PHASE2":4773,"PHASE3":4775,"PHASE4":4777,"NA":4779},{"trials":4770,"activeCount":98},[],{"trials":4772,"activeCount":98},[],{"trials":4774,"activeCount":98},[],{"trials":4776,"activeCount":98},[],{"trials":4778,"activeCount":98},[],{"trials":4780,"activeCount":98},[4781],{"nctId":4782,"briefTitle":4783,"status":214,"phases":4784,"primaryCompletion":4785,"completion":4786,"start":4787,"enrollment":1927,"conditions":4788,"interventions":4791},"NCT05202015","Non-invasive MRI Subclassification of Heptocellular Carcinoma - HepCaSt-Study",[],"2024-01-01","2024-07-01","2022-01-01",[4789,986,4790],"HCC","MRI",[4767],{"intervention":4793,"totalTrials":94,"cells":4794},"Levosimendan",{"EARLY_PHASE1":4795,"PHASE1":4797,"PHASE2":4799,"PHASE3":4801,"PHASE4":4803,"NA":4805},{"trials":4796,"activeCount":98},[],{"trials":4798,"activeCount":98},[],{"trials":4800,"activeCount":98},[],{"trials":4802,"activeCount":98},[],{"trials":4804,"activeCount":98},[],{"trials":4806,"activeCount":98},[4807],{"nctId":4808,"briefTitle":4809,"status":564,"phases":4810,"primaryCompletion":1536,"completion":1536,"start":1829,"enrollment":4811,"conditions":4812,"interventions":4814},"NCT02275013","Levosimendan Administration and Outcome in Cardiac Surgery",[],159,[4813],"Treatment of Left Heart Insufficiency in an Operative Setting of Cardiac Surgery",[4793],{"intervention":4816,"totalTrials":94,"cells":4817},"Oxytocin nasal spray",{"EARLY_PHASE1":4818,"PHASE1":4820,"PHASE2":4822,"PHASE3":4824,"PHASE4":4826,"NA":4828},{"trials":4819,"activeCount":98},[],{"trials":4821,"activeCount":98},[],{"trials":4823,"activeCount":98},[],{"trials":4825,"activeCount":98},[],{"trials":4827,"activeCount":98},[],{"trials":4829,"activeCount":98},[4830],{"nctId":4831,"briefTitle":4832,"status":564,"phases":4833,"primaryCompletion":4834,"completion":4834,"start":4835,"enrollment":4836,"conditions":4837,"interventions":4838},"NCT03031405","The Effect of Oxytocin on the Acquisition and Consolidation of Trauma-Associated Memories",[91],"2018-06-30","2017-01-15",220,[523],[4816,4839],"Placebos",{"intervention":4839,"totalTrials":94,"cells":4841},{"EARLY_PHASE1":4842,"PHASE1":4844,"PHASE2":4846,"PHASE3":4848,"PHASE4":4850,"NA":4852},{"trials":4843,"activeCount":98},[],{"trials":4845,"activeCount":98},[],{"trials":4847,"activeCount":98},[],{"trials":4849,"activeCount":98},[],{"trials":4851,"activeCount":98},[],{"trials":4853,"activeCount":98},[4854],{"nctId":4831,"briefTitle":4832,"status":564,"phases":4855,"primaryCompletion":4834,"completion":4834,"start":4835,"enrollment":4836,"conditions":4856,"interventions":4857},[91],[523],[4816,4839],{"intervention":4859,"totalTrials":94,"cells":4860},"Duloxetine",{"EARLY_PHASE1":4861,"PHASE1":4863,"PHASE2":4865,"PHASE3":4867,"PHASE4":4869,"NA":4871},{"trials":4862,"activeCount":98},[],{"trials":4864,"activeCount":98},[],{"trials":4866,"activeCount":98},[],{"trials":4868,"activeCount":98},[],{"trials":4870,"activeCount":98},[],{"trials":4872,"activeCount":98},[4873],{"nctId":4874,"briefTitle":4875,"status":214,"phases":4876,"primaryCompletion":3163,"start":869,"enrollment":983,"conditions":4877,"interventions":4879},"NCT00596986","Getting Biased Treatment Study: How Psychotherapy and Antidepressants Change Brain Activity in Chronic Depression",[91],[4878],"Chronic Depression",[4859],{"intervention":4881,"totalTrials":94,"cells":4882},"lipid\u002Fheparin",{"EARLY_PHASE1":4883,"PHASE1":4885,"PHASE2":4887,"PHASE3":4889,"PHASE4":4891,"NA":4893},{"trials":4884,"activeCount":98},[],{"trials":4886,"activeCount":98},[],{"trials":4888,"activeCount":98},[],{"trials":4890,"activeCount":98},[],{"trials":4892,"activeCount":98},[],{"trials":4894,"activeCount":98},[4895],{"nctId":4896,"briefTitle":4897,"status":564,"phases":4898,"primaryCompletion":203,"completion":203,"start":1766,"enrollment":228,"conditions":4899,"interventions":4902},"NCT00473603","Effect of Free Fatty Acids (FFA) on Androgen Precursors in Women",[91],[4900,4901],"Hyperandrogenism","Glucocorticoid Metabolism",[4881],{"intervention":4904,"totalTrials":94,"cells":4905},"Leeches",{"EARLY_PHASE1":4906,"PHASE1":4908,"PHASE2":4910,"PHASE3":4912,"PHASE4":4914,"NA":4916},{"trials":4907,"activeCount":98},[],{"trials":4909,"activeCount":98},[],{"trials":4911,"activeCount":98},[],{"trials":4913,"activeCount":98},[],{"trials":4915,"activeCount":98},[],{"trials":4917,"activeCount":98},[4918],{"nctId":4919,"briefTitle":4920,"status":201,"phases":4921,"primaryCompletion":4436,"completion":4436,"start":4922,"enrollment":4923,"conditions":4924,"interventions":4926},"NCT03020368","Effectiveness and Safety of Breeded Leech for Symptomatic Primary Arthrosis of the First Carpometacarpal Joint",[91],"2017-01",52,[4925],"Rhizarthrosis",[4904,4927],"Diclofenac",{"intervention":4927,"totalTrials":94,"cells":4929},{"EARLY_PHASE1":4930,"PHASE1":4932,"PHASE2":4934,"PHASE3":4936,"PHASE4":4938,"NA":4940},{"trials":4931,"activeCount":98},[],{"trials":4933,"activeCount":98},[],{"trials":4935,"activeCount":98},[],{"trials":4937,"activeCount":98},[],{"trials":4939,"activeCount":98},[],{"trials":4941,"activeCount":98},[4942],{"nctId":4919,"briefTitle":4920,"status":201,"phases":4943,"primaryCompletion":4436,"completion":4436,"start":4922,"enrollment":4923,"conditions":4944,"interventions":4945},[91],[4925],[4904,4927],{"intervention":4947,"totalTrials":94,"cells":4948},"cetirizine dihydrochloride",{"EARLY_PHASE1":4949,"PHASE1":4951,"PHASE2":4953,"PHASE3":4955,"PHASE4":4957,"NA":4959},{"trials":4950,"activeCount":98},[],{"trials":4952,"activeCount":98},[],{"trials":4954,"activeCount":98},[],{"trials":4956,"activeCount":98},[],{"trials":4958,"activeCount":98},[],{"trials":4960,"activeCount":98},[4961],{"nctId":4962,"briefTitle":4963,"status":564,"phases":4964,"primaryCompletion":4965,"completion":4965,"start":578,"enrollment":4966,"conditions":4967,"interventions":4969},"NCT00610584","Acupuncture for Seasonal Allergic Rhinitis",[91],"2011-04",422,[4968],"Seasonal Allergic Rhinitis",[4947],{"intervention":4971,"totalTrials":94,"cells":4972},"\"Yohimbine\"",{"EARLY_PHASE1":4973,"PHASE1":4975,"PHASE2":4977,"PHASE3":4979,"PHASE4":4981,"NA":4983},{"trials":4974,"activeCount":98},[],{"trials":4976,"activeCount":98},[],{"trials":4978,"activeCount":98},[],{"trials":4980,"activeCount":98},[],{"trials":4982,"activeCount":98},[],{"trials":4984,"activeCount":98},[4985],{"nctId":4986,"briefTitle":4987,"status":564,"phases":4988,"primaryCompletion":4989,"completion":4989,"start":4990,"enrollment":4991,"conditions":4992,"interventions":4995},"NCT04359147","The Role of Stress Neuromodulators in Decision Making Under Risk and Selective Attention to Threat",[91],"2021-12-22","2019-11-01",167,[4558,4401,4993,4994],"Yohimbine + Hydrocortisone","Placebo",[4971,4996,4997,4998],"\"Hydrocortisone\"","\"Yohimbine + Hydrocortisone\"","\"Placebo\"",{"intervention":4996,"totalTrials":94,"cells":5000},{"EARLY_PHASE1":5001,"PHASE1":5003,"PHASE2":5005,"PHASE3":5007,"PHASE4":5009,"NA":5011},{"trials":5002,"activeCount":98},[],{"trials":5004,"activeCount":98},[],{"trials":5006,"activeCount":98},[],{"trials":5008,"activeCount":98},[],{"trials":5010,"activeCount":98},[],{"trials":5012,"activeCount":98},[5013],{"nctId":4986,"briefTitle":4987,"status":564,"phases":5014,"primaryCompletion":4989,"completion":4989,"start":4990,"enrollment":4991,"conditions":5015,"interventions":5016},[91],[4558,4401,4993,4994],[4971,4996,4997,4998],{"intervention":4997,"totalTrials":94,"cells":5018},{"EARLY_PHASE1":5019,"PHASE1":5021,"PHASE2":5023,"PHASE3":5025,"PHASE4":5027,"NA":5029},{"trials":5020,"activeCount":98},[],{"trials":5022,"activeCount":98},[],{"trials":5024,"activeCount":98},[],{"trials":5026,"activeCount":98},[],{"trials":5028,"activeCount":98},[],{"trials":5030,"activeCount":98},[5031],{"nctId":4986,"briefTitle":4987,"status":564,"phases":5032,"primaryCompletion":4989,"completion":4989,"start":4990,"enrollment":4991,"conditions":5033,"interventions":5034},[91],[4558,4401,4993,4994],[4971,4996,4997,4998],{"intervention":4998,"totalTrials":94,"cells":5036},{"EARLY_PHASE1":5037,"PHASE1":5039,"PHASE2":5041,"PHASE3":5043,"PHASE4":5045,"NA":5047},{"trials":5038,"activeCount":98},[],{"trials":5040,"activeCount":98},[],{"trials":5042,"activeCount":98},[],{"trials":5044,"activeCount":98},[],{"trials":5046,"activeCount":98},[],{"trials":5048,"activeCount":98},[5049],{"nctId":4986,"briefTitle":4987,"status":564,"phases":5050,"primaryCompletion":4989,"completion":4989,"start":4990,"enrollment":4991,"conditions":5051,"interventions":5052},[91],[4558,4401,4993,4994],[4971,4996,4997,4998],{"intervention":5054,"totalTrials":94,"cells":5055},"Molecular guided therapy",{"EARLY_PHASE1":5056,"PHASE1":5058,"PHASE2":5060,"PHASE3":5062,"PHASE4":5064,"NA":5066},{"trials":5057,"activeCount":98},[],{"trials":5059,"activeCount":98},[],{"trials":5061,"activeCount":98},[],{"trials":5063,"activeCount":98},[],{"trials":5065,"activeCount":98},[],{"trials":5067,"activeCount":98},[5068],{"nctId":5069,"briefTitle":5070,"status":564,"phases":5071,"primaryCompletion":5072,"completion":5073,"start":4429,"enrollment":5074,"conditions":5075,"interventions":5077},"NCT05063058","Biomarker-driven Therapy for Melanoma",[91],"2019-11","2021-08",100,[5076],"Melanoma",[5054],{"intervention":5079,"totalTrials":94,"cells":5080},"Midazolam vs. Lormetazepam",{"EARLY_PHASE1":5081,"PHASE1":5083,"PHASE2":5085,"PHASE3":5087,"PHASE4":5089,"NA":5091},{"trials":5082,"activeCount":98},[],{"trials":5084,"activeCount":98},[],{"trials":5086,"activeCount":98},[],{"trials":5088,"activeCount":98},[],{"trials":5090,"activeCount":98},[],{"trials":5092,"activeCount":98},[5093],{"nctId":5094,"briefTitle":5095,"status":564,"phases":5096,"primaryCompletion":5097,"completion":5097,"start":5098,"enrollment":5099,"conditions":5100,"interventions":5101},"NCT04408911","Lormetazepam Versus Midazolam in Critically Ill Patients: a Retrospective Cohort Trial",[],"2018-12-31","2006-01-01",3314,[28],[5079],{"intervention":5103,"totalTrials":94,"cells":5104},"Teduglutide",{"EARLY_PHASE1":5105,"PHASE1":5107,"PHASE2":5109,"PHASE3":5111,"PHASE4":5113,"NA":5115},{"trials":5106,"activeCount":98},[],{"trials":5108,"activeCount":98},[],{"trials":5110,"activeCount":98},[],{"trials":5112,"activeCount":98},[],{"trials":5114,"activeCount":98},[],{"trials":5116,"activeCount":98},[5117],{"nctId":5118,"briefTitle":5119,"status":214,"phases":5120,"primaryCompletion":5121,"completion":5122,"start":5123,"enrollment":568,"conditions":5124,"interventions":5127},"NCT04733066","Quality of Life in Patients With Short Bowel Syndrome Treated Without and With Teduglutide - a Prospective Nested Matched Pair Analysis",[],"2021-09","2022-09","2020-09-01",[5125,5126],"Short Bowel Syndrome","Intestinal Failure",[5103],{"intervention":5129,"totalTrials":94,"cells":5130},"Lamotrigine",{"EARLY_PHASE1":5131,"PHASE1":5133,"PHASE2":5135,"PHASE3":5137,"PHASE4":5139,"NA":5141},{"trials":5132,"activeCount":98},[],{"trials":5134,"activeCount":98},[],{"trials":5136,"activeCount":98},[],{"trials":5138,"activeCount":98},[],{"trials":5140,"activeCount":98},[],{"trials":5142,"activeCount":98},[5143],{"nctId":5144,"briefTitle":5145,"status":564,"phases":5146,"primaryCompletion":5147,"completion":5147,"start":5148,"enrollment":2284,"conditions":5149,"interventions":5151},"NCT04156035","Ketamine-Induced Brain Changes and Their Modulation by Lamotrigine",[91],"2020-12-10","2020-03-10",[5150],"Emotions",[5129,5152],"Ketamine",{"intervention":5152,"totalTrials":94,"cells":5154},{"EARLY_PHASE1":5155,"PHASE1":5157,"PHASE2":5159,"PHASE3":5161,"PHASE4":5163,"NA":5165},{"trials":5156,"activeCount":98},[],{"trials":5158,"activeCount":98},[],{"trials":5160,"activeCount":98},[],{"trials":5162,"activeCount":98},[],{"trials":5164,"activeCount":98},[],{"trials":5166,"activeCount":98},[5167],{"nctId":5144,"briefTitle":5145,"status":564,"phases":5168,"primaryCompletion":5147,"completion":5147,"start":5148,"enrollment":2284,"conditions":5169,"interventions":5170},[91],[5150],[5129,5152],{"intervention":5172,"totalTrials":94,"cells":5173},"Chemotherapy",{"EARLY_PHASE1":5174,"PHASE1":5176,"PHASE2":5178,"PHASE3":5180,"PHASE4":5182,"NA":5184},{"trials":5175,"activeCount":98},[],{"trials":5177,"activeCount":98},[],{"trials":5179,"activeCount":98},[],{"trials":5181,"activeCount":98},[],{"trials":5183,"activeCount":98},[],{"trials":5185,"activeCount":98},[5186],{"nctId":5187,"briefTitle":5188,"status":214,"phases":5189,"primaryCompletion":5190,"completion":5191,"start":5192,"enrollment":2772,"conditions":5193,"interventions":5196},"NCT02753036","Chemotherapy-induced Cognitive Alterations in Recruits With Ovarian and Breast Cancer",[],"2022-12-31","2023-06-30","2016-01-01",[5194,5195],"Cognition Disorders","Polyneuropathies",[5172],{"intervention":5198,"totalTrials":94,"cells":5199},"Methylphenidate 20 mg tablet given once by mouth",{"EARLY_PHASE1":5200,"PHASE1":5202,"PHASE2":5204,"PHASE3":5206,"PHASE4":5208,"NA":5210},{"trials":5201,"activeCount":98},[],{"trials":5203,"activeCount":98},[],{"trials":5205,"activeCount":98},[],{"trials":5207,"activeCount":98},[],{"trials":5209,"activeCount":98},[],{"trials":5211,"activeCount":98},[5212],{"nctId":5213,"briefTitle":5214,"status":564,"phases":5215,"primaryCompletion":5216,"completion":5216,"start":4415,"enrollment":2783,"conditions":5217,"interventions":5218},"NCT02071615","Effects of Modafinil, Caffeine and Methylphenidate in Healthy Volunteers",[91],"2014-03",[18],[5198,5219,5220],"modafinil 200mg tablet given once by mouth","caffein 200mg tablet given once by mouth",{"intervention":5219,"totalTrials":94,"cells":5222},{"EARLY_PHASE1":5223,"PHASE1":5225,"PHASE2":5227,"PHASE3":5229,"PHASE4":5231,"NA":5233},{"trials":5224,"activeCount":98},[],{"trials":5226,"activeCount":98},[],{"trials":5228,"activeCount":98},[],{"trials":5230,"activeCount":98},[],{"trials":5232,"activeCount":98},[],{"trials":5234,"activeCount":98},[5235],{"nctId":5213,"briefTitle":5214,"status":564,"phases":5236,"primaryCompletion":5216,"completion":5216,"start":4415,"enrollment":2783,"conditions":5237,"interventions":5238},[91],[18],[5198,5219,5220],{"intervention":5220,"totalTrials":94,"cells":5240},{"EARLY_PHASE1":5241,"PHASE1":5243,"PHASE2":5245,"PHASE3":5247,"PHASE4":5249,"NA":5251},{"trials":5242,"activeCount":98},[],{"trials":5244,"activeCount":98},[],{"trials":5246,"activeCount":98},[],{"trials":5248,"activeCount":98},[],{"trials":5250,"activeCount":98},[],{"trials":5252,"activeCount":98},[5253],{"nctId":5213,"briefTitle":5214,"status":564,"phases":5254,"primaryCompletion":5216,"completion":5216,"start":4415,"enrollment":2783,"conditions":5255,"interventions":5256},[91],[18],[5198,5219,5220],{"intervention":5258,"totalTrials":94,"cells":5259},"Oxytocin",{"EARLY_PHASE1":5260,"PHASE1":5262,"PHASE2":5264,"PHASE3":5266,"PHASE4":5268,"NA":5270},{"trials":5261,"activeCount":98},[],{"trials":5263,"activeCount":98},[],{"trials":5265,"activeCount":98},[],{"trials":5267,"activeCount":98},[],{"trials":5269,"activeCount":98},[],{"trials":5271,"activeCount":98},[5272],{"nctId":5273,"briefTitle":5274,"status":564,"phases":5275,"primaryCompletion":5276,"completion":5277,"start":5278,"enrollment":5279,"conditions":5280,"interventions":5281},"NCT03875391","The Effect of Oxytocin on the Consolidation of Trauma-Associated Memories",[91],"2020-12-31","2021-03-31","2019-03-06",217,[523,522],[5258],{"intervention":5283,"totalTrials":94,"cells":5284},"epoetin beta",{"EARLY_PHASE1":5285,"PHASE1":5287,"PHASE2":5289,"PHASE3":5291,"PHASE4":5293,"NA":5295},{"trials":5286,"activeCount":98},[],{"trials":5288,"activeCount":98},[],{"trials":5290,"activeCount":98},[],{"trials":5292,"activeCount":98},[],{"trials":5294,"activeCount":98},[],{"trials":5296,"activeCount":98},[5297],{"nctId":5298,"briefTitle":5299,"status":564,"phases":5300,"primaryCompletion":5301,"completion":5301,"start":5302,"enrollment":5303,"conditions":5304,"interventions":5306},"NCT00593801","Erythropoietin Treatment in Extremely Low Birth Weight Infants",[91],"1999-06","1998-05",219,[5305,1037],"Infant, Low Birth Weight",[5283,5283],{"intervention":5308,"totalTrials":94,"cells":5309},"Gene Panel Sequencing",{"EARLY_PHASE1":5310,"PHASE1":5312,"PHASE2":5314,"PHASE3":5316,"PHASE4":5318,"NA":5320},{"trials":5311,"activeCount":98},[],{"trials":5313,"activeCount":98},[],{"trials":5315,"activeCount":98},[],{"trials":5317,"activeCount":98},[],{"trials":5319,"activeCount":98},[],{"trials":5321,"activeCount":98},[5322],{"nctId":5323,"briefTitle":5324,"status":564,"phases":5325,"primaryCompletion":5326,"completion":5327,"start":5328,"enrollment":2355,"conditions":5329,"interventions":5331},"NCT02380729","Mutation Exploration in Non-acquired, Genetic Disorders and Its Impact on Health Economy and Life Quality",[],"2017-06-30","2017-12-31","2015-01-31",[5330],"Genetic Diseases",[5308,5332],"Whole Genome Sequencing",{"intervention":5332,"totalTrials":94,"cells":5334},{"EARLY_PHASE1":5335,"PHASE1":5337,"PHASE2":5339,"PHASE3":5341,"PHASE4":5343,"NA":5345},{"trials":5336,"activeCount":98},[],{"trials":5338,"activeCount":98},[],{"trials":5340,"activeCount":98},[],{"trials":5342,"activeCount":98},[],{"trials":5344,"activeCount":98},[],{"trials":5346,"activeCount":98},[5347],{"nctId":5323,"briefTitle":5324,"status":564,"phases":5348,"primaryCompletion":5326,"completion":5327,"start":5328,"enrollment":2355,"conditions":5349,"interventions":5350},[],[5330],[5308,5332]]